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Abstract
Primary breast augmentation is one of the most common surgeries performed by
plastic surgeons. Breast augmentation, since its inception in 1895, has become a
multimillion-dollar industry. Today, the two most common methods include implant-based
and fat graft augmentation. Implant-based augmentation includes the use of silicone or saline
prosthesis to enhance breast volume or shape. With fat grafting, a patient’s fat is harvested,
processed, and injected into the breast to achieve the desired result. This thesis aims to
outline the current literature on both methods of breast augmentation, review patient reported
outcomes, as well as a proposed clinical trial to gain further understanding into fat grafting to
address the current deficiencies in the literature.

Keywords
Breast augmentation, Breast Implants, Fat grafting, BreastQ, cosmetic breast surgery,
reconstructive breast surgery.
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Summary for Lay Audience
Patients undergo breast surgery for either cosmetic or reconstructive (breasts removed
due to cancer or for lack of normal breast development) indications. Breast augmentation is
one of the most common procedures performed by plastic surgeons. Breast implants have
been a standard option for breast augmentation for the past 60 years. However, in the past
decade a large group of patients are requesting a more ‘natural’ option to enhance their
breast, with no prosthetic implant.
Fat grafting provides an option for breast enhancement using the patient’s own tissue.
The fat grafting procedure involves liposuction to the abdomen, thighs, or buttocks. The
harvested fat is then processed and prepared for injection into the breast. During surgery the
fat is injected into the breast, balancing the desired result and limitations of injectable
volume. This procedure can produce great initial results; however, long-term fat graft
survival can be unpredictable. The injected fat, over time, may not survive. This can result in
the body breaking down the non-viable fat, creating hard and painful nodules, and ultimately
losing a volume of the injected fat. This has limited the widespread adoption of this
technique.

In this thesis the current data is reviewed on the above methods, as well as patient
satisfaction surveys. Secondly, a proposed clinical trial looking into fat grafting. This will
give us more knowledge on how to treat the fat during surgery, to increase the amount of fat
survival after surgery.

iii

List of Acronyms
ADM – Acellular dermal matrix
ADSC – Adipose derived stem cell
AFG – Autologous fat grafting
ASPS – American society of plastic surgery
BEQ – Breast evaluation Questionnaire
BIA-ALCL – Breast Implant associated - Anaplastic Large Cell Lymphoma
BII – Breast Implant Illness
BIS – Breast Implant sickness
BMI – Body mass index
BRASSQ - Breast reduction assessed severity scale questionnaire
CC – Capsular contracture
CI – Confidence Interval
CT – Computerized tomography
DIEP – Deep inferior epigastric perforator
FDA – Food and Drug Administration
IMF – Infra mammary fold
IQR – Inter quartile range
ISAPS – International society of Aesthetic Plastic Surgeons
LAP – Lumbar artery perforator
LHSC – London health sciences center
LOI – Letter of Information
MINORS - Methodological Index for Non-Randomized studies
MRI – Magnetic Resonance imaging
NAC – Nipple areolar complex
NR – Not reported
PAP – Profunda artery perforator
PET – Positron emission tomography
PRISMA - Preferred Reporting Items for Systematic Reviews and Meta- Analysis
PROM – Patient reported outcome measure
PRP – Platelet rich plasma
PRSJ – Plastic and Reconstructive surgery journal
QOL – Quality of Life
RCT – Randomized controlled trial
REB – Research ethics board
RR – Relative risk
SD – Standard deviation
SVF – Stromal vascular factor
TE – Tissue expander
TRAM – Transverse rectus abdominus muscle

iv

Co-Authorship Statement

Chapter 1 –Kathryn Minkhorst and Katrina Jackzul are credited for their help with the
database search. Drs. Simpson, DeLyzer, Symonette and Yazdani contributed their guidance
and review of the manuscript.
Chapter 2 – Literature search and data extraction were done by Kathryn Minkhorst and
Katrina Jackzul. The statistical analysis was completed by a statistician, Leonardo Guizzetti.
Drs. Appleton, DeLyzer and Yazdani are credited for their guidance and review of the
manuscript.
Chapter 3 – Drs. DeLyzer and Yazdani are credited for their guidance and review of the trial.
Kalan Lynn was also instrumental in her help and support with the Research Ethics
submission.
Chapter 4 – Drs. Simpson and Brackstone are credited for their advice regarding structure
and content.

v

Acknowledgments
I am honored to have had the opportunity to complete the Master of Surgery program and the
opportunity to work alongside such an incredible group of surgeon-scientists.
Firstly, Dr. Andrew Simpson, I am very grateful for all your guidance over the past few
years. None of this would be possible, without you and your support. You have been
instrumental in my thesis and all our other little projects!
Dr. Muriel Brackstone, your enthusiasm, wisdom and input have been inspiring. You made
the completion of my masters possible and showed me the light at the end of the tunnel. I am
truly indebted to you.

To my committee members,
Dr. Arjang Yazdani, your advice on and off ‘the pitch’ have been invaluable. I am truly lucky
to have your mentorship throughout this process. Dr. Caitlin Symonette, your commitment to
research, innovation and positive attitude has made it a truly rewarding experience. I am
genuinely thankful to have you both on my masters committee.

Dr. Tanya DeLyzer, thank you for all your help, time, and advice. Your wealth of knowledge
has improved all my projects. Your input as principal investigator and guidance throughout
the process, have made the clinical trial a reality.

Finally, I want to thank my family and friends for all their support and motivation to keep
going!

vi

Table of Contents
ABSTRACT ................................................................................................................................................... II
SUMMARY FOR LAY AUDIENCE ........................................................................................................... III
LIST OF ACRONYMS.................................................................................................................................IV
CO-AUTHORSHIP STATEMENT ..............................................................................................................V
ACKNOWLEDGMENTS.............................................................................................................................VI
TABLE OF CONTENTS ............................................................................................................................ VII
THESIS OUTLINE................................................................................................................................................ IX
1

BREAST AUGMENTATION – A LITERATURE REVIEW ............................................................. 1
1.1

INTRODUCTION .................................................................................................................................... 1

1.2

BREAST IMPLANTS ............................................................................................................................... 3

1.3

FAT GRAFTING ................................................................................................................................... 14

1.4

AUTOLOGOUS BREAST RECONSTRUCTION ......................................................................................... 26

1.5

CONCLUSION ...................................................................................................................................... 27

CHAPTER 1 – REFERENCES ................................................................................................................... 28
2

FAT GRAFTING VS. IMPLANTS: WHO’S HAPPIER? A SYSTEMATIC REVIEW AND META-

ANALYSIS .................................................................................................................................................. 36
2.1

BACKGROUND .................................................................................................................................... 36

2.2

METHODS........................................................................................................................................... 40

2.3

RESULTS ............................................................................................................................................ 45

2.4

DISCUSSION ....................................................................................................................................... 63

2.5

CONCLUSION ...................................................................................................................................... 67

2.6

FUTURE IMPLICATIONS ...................................................................................................................... 67

CHAPTER 2 – REFERENCES ................................................................................................................... 69
3

THE FAT ANALYSIS TRIAL (FAT): A DOUBLE BLINDED PROSPECTIVE RANDOMIZED

CONTROLLED TRIAL .............................................................................................................................. 72
3.1

BACKGROUND .................................................................................................................................... 72

3.2

METHODS............................................................................................................................................. 76

3.3

CONCLUSION ...................................................................................................................................... 82

CHAPTER 3 – REFERENCES ................................................................................................................... 83
vii

4

DISCUSSION ..................................................................................................................................... 86
4.1

INTRODUCTION .................................................................................................................................. 86

4.2

PATIENT SELECTION ........................................................................................................................... 86

4.3

OPERATIVE CONSIDERATIONS............................................................................................................ 87

4.4

LIMITATIONS ......................................................................................................................................... 91

4.5

CONCLUSION ...................................................................................................................................... 92

APPENDIX 1 – BREAST RECONSTRUCTION ARTICLE ..................................................................... 93
APPENDIX 2 – SEARCH STRATEGY .................................................................................................... 119
APPENDIX 3 – LETTER OF INFORMATION ....................................................................................... 123
.................................................................................................................................................................... 123
APPENDIX 4 – BREASTQ ....................................................................................................................... 132
CURRICULUM VITAE ............................................................................................................................ 146

viii

Thesis Outline

In Chapter 1, a literature review of available data and information on breast
augmentation is performed. Particularly, addressing concerns with prosthetics and their
associated complications. The review will further highlight current surgical recommendations
and best practice guidelines. Finally, the review highlights fat grafting, including current
techniques, analysis, pathophysiology, and theories associated with fat survival.
In Chapter 2, the thesis addresses breast augmentation satisfaction from the patients’
perspective. The comprehensive meta-analysis of qualitative data available in the literature
from patient reported outcome measures is evaluated. The thesis will compare the two most
popular methods of breast augmentation, implants, and fat grafting to gain further
understanding regarding the patient’s quality of life.
In Chapter 3, the lack of information truly known regarding fat grafting, retention,
survival, and best surgical practice are highlighted. The thesis further proposes a randomized
controlled trial to help address current deficiencies in our knowledge, to help guide future
practice, increase patient safety and satisfaction.
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Breast Augmentation – A literature review

Breast Augmentation is a popular surgical procedure that is well described in the
surgical literature. The most common method of surgical augmentation relies on
alloplastic implants and in fact these are one of the most common surgical prosthetic
devices in North America. This chapter will broadly outline the currently available breast
implant categories (silicone and saline), surgical adjuncts, surgical techniques, and
complications. This review will also highlight alternative methods of breast
augmentation, particularly, fat grafting. Outlining what is currently understood regarding
the pathophysiology and survival of fat, current surgical recommendations, fat enhancers,
fat analysis and finally, future trends.
This chapter has been modified from a manuscript for the purpose of this thesis. The
manuscript is currently pending submission to the European Journal of Plastic Surgery.

1.1
1.1.1

Introduction
Anatomy
Anatomically, the breast extends from the second rib to below the sixth rib and

spans from the mid-axillary line to the sternum laying over top of pectoralis major, with
most of the tissue situated in the upper outer quadrant. (1,2) The skin is the most
superficial layer, and it merges with the superficial fascia that envelopes the breast
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parenchyma with the deep fascia. This is particularly important as the convergence of
superficial and deep layers create the infra-mammary fold. (2) The nipple is located at the
level of the fourth intercostal space and contains 15-20 lactiferous ducts. It is surrounded
by the areola which has visible sebaceous glands and smooth muscle fibers for nipple
erection. (1,2) The blood supply to the breasts is via branches from the axillary, internal
thoracic, and intercostal arteries. (1,2) Venous drainage follows the arterial supply
through the internal mammary vein, tributaries of the axillary vein, and intercostal veins.
(2) The lymphatic drainage of the deep parts of the breasts is through the axillary (75%)
and internal thoracic lymph nodes. The superficial layer of the breast is drained by
Sappey’s plexus. (1,2) Sensory innervation to the breast is through the lateral cutaneous
branch of the sixth intercostal nerves and the nipple-areola complex (NAC) itself is
innervated by the fourth intercostal nerve. (2)

1.1.2

Rationale
A patient’s decision to undergo a breast augmentation is multi-factorial, but the

primary three reasons include cosmesis, reconstruction, and correction of congenital
deformities. (3) An individual’s decision and rationale are often complex and may
include a multitude of personal, social, and cultural contexts. (4) Several reasons an
individual may choose to undergo breast augmentation is to improve self-esteem, selfacceptance, sexual interest, and to better express an individual’s gender identity.
Regarding the reconstructive population, it can reduce stress, anxiety, restore wholeness
and well-being in patients who have gone through their breast cancer journey. (5,6)
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Cosmetic breast augmentation is growing in popularity and has seen a 41%
increase since 2010 and is one of the most common procedures in North America. (7,8)
In the United States in 2017, there was over 300,000 breast augmentation surgeries
performed, and 299,715 surgeries in 2019. (7,8) Data from the international association
of aesthetic plastic surgeons (ISAPS) from 2019 (pre-pandemic), showed that breast
augmentation was the most common procedure internationally with 1,795,551 surgeries
performed. This was followed by liposuction at 1,704,786 procedures internationally.
(7,8) The two most common methods for cosmetic breast augmentation are fat grafting
and implant-based augmentation procedures, with implants being significantly more
popular overall (29% vs 71%). (7) The majority of patients who undergo breast
augmentation, according to North American data, are Caucasian, female, middle to upper
socioeconomic status, married, between the ages of 20 to 40 years old, with children.
(9,10)
The objective of this review is to evaluate the currently available literature,
describe the most popular techniques and assess current trends.

1.2
1.2.1

Breast Implants
Historical Overview

Breast implants date back to 1895 when Vincenz Czerny used a lipoma to correct
a breast defect after a mastectomy. (3,11) In the early 1900’s breast implants were
experimental, taking the form of glass balls, ground rubber, polyvinyl alcohol3
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formaldehyde polymer sponges, and polyether foam sponges, and by 1954, breast
augmentation was performed using adipose tissue and omentum to augment the breast.
(3,12) Polyurethane, polytetrafluoroethylene (Teflon), epoxy resin, shellac, beeswax,
paraffin, rubber, petroleum jelly, and liquefied silicon became popular materials used in
breast implantation. (3) In 1961, the first modern breast implant was made as a silicone
gel implant, and saline implants followed in 1965. (3) Silicone implants gained popularity
in the 1980s, however in the early 1990’s an ever-growing subset of patients experienced
implant ruptures. The ruptured silicone led to multiple lawsuits from patients, associating
the silicone with connective tissue disorders, such as Sjogren’s, Scleroderma,
Rheumatoid arthritis, as well as melanoma and stillbirths. The long list of lawsuits, as
well as the growing public demand at the time, led the FDA (Food and Drug
administration, USA) to ban the use of silicone implants in 1992. The leading
manufacturer of silicone implants at the time, Dow Corning, filed for bankruptcy in 1995.
(PMC1676088).
A landmark paper, published by the institute of medicine in 1999, showed that
there was no evidence to associate the above conditions with silicone implants
(www.iom.edu/CMS/3793/5638.aspx). The growing body of medical literature, along
with clinical data from countries still using silicone at the time of the ban, showed that
silicone implants were safe. The reassuring clinical data allowed the FDA to approve the
use of silicone implants from Allergan and Mentor in 2006. Silicone implants are now the
most popular type of breast implant, with FDA approval for cosmetic and reconstructive
purposes in patients over the age of 22. (3,7,9,11)
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1.2.2

Implant Properties
The two main types of material used to fill implants are silicone and saline.

Silicone breast implants are by far the most common type of material used in cosmetic
breast augmentation (90% vs 10%). (13,14) Silicone is more expensive but has a more
natural feel and is offered in a greater variety of shapes. (7,11) The volume and density of
the gel inside the implant will ultimately affect how natural it will feel. (15) Although, in
endoscopic trans-axillary and trans-umbilical breast augmentation, saline implants are the
only option for minimally invasive surgery. (16)
Saline implants pose a five-time higher risk of rupture in the short term (2.5% vs
0.5%), and it may feel less ‘breast like’ given the lower density of saline compared to
natural breast tissue. (17) If a silicone implant ruptures, it does not always require surgery
for removal. The ‘ruptured’ content is typically contained in the capsule, this would
therefore not affect the overall cosmetic appearance. In certain cases, when the person is
symptomatic, or the rupture has affected the cosmetic outcome, a second surgery would
be needed to replace the implant. (18)
Breast implants come in two main shapes, round and anatomical. (3) An external
texture is a requirement of anatomical implants as it is thought to increase friction and
avoid unwanted movement and rotation. Anatomical implants (tear-drop shaped,
flattened on the aspect that lies against the chest wall) offer a more natural shape, but
they are more expensive and have a higher risk of malrotation. This occurs when the
implant moves within the pocket and causes the breast to look abnormally shaped. (19)
Round implants inherently give a fuller look in the upper pole, which leads to the
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potential of having an un-natural result. This must be considered in the pre-operative
assessment. (20)
Projection is affected by the base diameter and height of the implant, as well as
the total volume. (21) Maximal projection is defined as the distance between the lower
aspect of the implant to the maximal distance the implant protrudes away from the body,
typically below the midline of the implant, which may change when the patient is prone
versus supine. (22,23) There is a huge variety of projections available to choose from.
The choice of projection is made between the surgeon and patient balancing patient
desire for post-augmentation/reconstruction breast shape and surgeon experience with
post-operative appearance and skin envelope capacity. (23)
Smooth implants are supple and can mimic the feel and movement of a natural
breast. (18) The textured surface, however, stabilizes the implant, disrupts the formation
of a capsule in a subpectoral plane augmentation, and help prevent certain post-operative
complications, including malrotation, which is only associated with anatomical implants,
as they have an asymmetric form-factor. (17,18) Breast animation causes movement of
the implant when pectoralis is engaged, causing an un-natural movement of the overlying
skin and nipple-areolar complex (NAC). (18,19)
A form of saline implant, known as tissue expanders (TE), are provided empty
and gradually filled with saline. (8,11) This offers a wider possibility of staging
procedures. This method creates a pocket and is slowly expanded during clinic visits to
accommodate the requested implant size. This is needed in two main situations, firstly,
when the breast tissue envelope, in its current state will not accommodate the required
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implant size and secondly, when then surrounding breast tissue requires further surgery
or radiation. (11,13)
In the first case, the tissue expander is inserted in a similar manner as a permanent
breast implant. The TE is filled to an appropriate volume intra-operatively to minimize
tension on the wound and breast tissue. During subsequent clinic visits, the TE, and more
importantly the injection port, can be identified with a magnet. This allows the clinician
to gradually inflate the tissue expander, over time, to achieve the desired size. (8,13,15)
Secondly, TE’s are commonly used as a temporary measure to maintain the implant
pocket. (3,8,11) This is most notable when the breast tissue will be undergoing radiation
post-operatively. The fibrosis caused by the radiation, not only thickens, and discolors the
skin, however, also causes a similar and more severe effect to the capsule around the
implant, which results in tightening of the pocket. (3,8) This can result in both a
cosmetically unacceptable breast placement, as well as pain. Although TE’s are a great
method in achieving certain results, there are several downsides. The use of TE’s will
require frequent clinic visits and inherently, a second surgery. (8,11) The frequent
needling can be a source of infection and if not done properly, cause the TE to rupture.
Certain newer TE’s, such as the BECKER implant (Mentor worldwide LLC, Irvine,
California, USA) has an external filling port, away from the expander, on the skin
surface, to avoid the above-mentioned complications.
Intra-operatively when there is insufficient tissue for coverage or support of the
implant. Acellular dermal matrices (ADMs) can be considered. In most cases the implant
is placed below the breast tissue, fascia, or muscle. (26,28) If the pocket is not adequate
to accommodate the implant, ADMs can be used to cover the exposed part of the implant
7
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and facilitate the formation of the capsule and therefore placement of the implant. ADMs
are a soft connective tissue mesh, from either human or animal origin. They are
decellularized to avoid an immune reaction, however, the structural matrix is preserved.
Surgical techniques will be discussed later in this chapter. (26,27,28,29)

1.2.3

Implant Surgical Technique
A major factor that affects the long-term outcome of breast augmentation, is the

location in which the implant is placed. Three main anatomic pockets: sub-muscular, subfascial and sub-glandular, as well as combinations of these, known as ‘dual-plane’, exist.
The major contributing factor in the decision of implant placement is dependent on
several factors including patient anatomy, surgeon preference, implant size, the soft tissue
envelope, patient characteristics and surgical approach. (24,25,30)
The more superficial planes, due to the weight of the implant and natural
physiology, are more susceptible to ptosis (the drooping of breast tissue from a more
youthful position, ideally with the NAC above the level of the IMF). (30) The deeper
planes, are more robust structures, attached to a bony component, therefore, more
resistant to mechanical drooping, as well as providing more tissue coverage to avoid
palpation of the implant. (24,25) The deeper pockets involve muscle dissection and are
therefore more painful and require a slightly longer recovery for patients. The muscle
being more superficial to the implant can also lead to certain deformities, known as
animation (breast implant movement when pectoralis is engaged) and window-shading
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(crease or dimple formed at the lower medial aspect of the breast when pectoralis is
engaged). (24,25,30)
There has been a significant amount of research published to decrease perioperative complications and increase patient safety. Research has shown that to reduce
the risk of infection, patients should receive IV antibiotics 30-60 minutes before skin
incision and an antibiotic solution to irrigate the pocket and allow it to rest there for at
least 5 minutes prior to the implant being inserted. (7,32) More so, before touching the
implant, all individuals involved in the surgery should change into a new set of sterile
gloves to minimize contamination. (7) Implants should be irrigated in the opened
packaging to minimize the risk of infection, using triple-solution (Cefazolin, Gentamicin
and Bacitracin in normal saline). (32) Breast implants should ideally not be handled. To
help maintain sterility, the no-touch technique has been described in the literature, which
uses a plastic sleeve provided or a reverse glove sleeve using a latex-free glove to insert
the implant after being bathed in a betadine and/or antibiotic solution. (32,38)
To further reduce the risk of infection, various methods have been created to
protect patients against the most common pathogens, Staphylococcus epidermidis and
Staphylococcus aureus. (39) The povidone-iodine solution has been shown to be the most
effective at reducing staphylococcus stains and Gram-positive bacteria but may weaken
the shell of silicone implants. (39) Triple-antibiotic saline irrigation is used after washing
the breast pocket with povidone-iodine and has demonstrated inconsistent benefits to
preventing implant infections but does not significantly reduce the risk of capsular
contracture or the overall risk of bacterial contamination. (39,40,41)
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1.2.4

Implant Related Complications
Early complications, within the first 30 days, after breast augmentation include

hematoma, seroma, infection, implant extrusion, and asymmetry. (31) Later
complications, past 30 days, include late seroma, double-capsule formation, and chronic
pain. (31) Physiologically, when an implant is inserted, the body begins to form a fibrous
capsule of tissue around the prosthetic. In most cases, this does not cause patients to
experience symptoms. However, in a certain subset of patients, they can experience
complications, including implant immobilization, pain, and discomfort, secondary to this
fibrous capsule contracting around the implant. This is known as a capsular contracture
(CC). There have been several classifications and staging systems proposed, however,
there is poor inter-observer reliability and they do not provide any specific treatment
algorithms. This highlights one of the main disadvantages of implants, and slightly more
so silicone implants, as they have an increased risk of capsular contracture, with an
incidence of approximately 5% compared to 2.8% for saline implants. (14) If a patient is
diagnosed with a capsular contracture, the resulting treatment, is operative removal of the
prosthetic implant, along with the complete or partial removal of the fibrous capsule. This
not only exposes patients to more operative time, to replace the implant, there is still a
possibility of getting a capsular contracture again with the new implants. (32,34)
The most common and least understood complication is capsular contracture (CC)
(ranging from 4-17%) which, as described earlier, can be painful and distort the shape
and volume of the breast, ultimately affecting the cosmetic result of the breast and the
patient’s quality of life. (31) It tends to occur within the first year after surgery, but can
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occur at any time post-operatively. (31,32,34) Capsular contracture has been associated
by several factors; a bacterial infection, and more specifically the formation of a subclinical staphylococcal biofilm has shown a very strong correlation with a clinically
symptomatic capsular contracture. (32,33,34) The literature has shown that a subglandular placement of the implant has been associated with a higher risk of CC. On the
other hand, a textured implant has been thought to make it more difficult for thick scar
tissue to adhere around the implant, thus reducing the risk. Drain placement and patient
factors have also been associated with the formation of CC, however, the overall
evidence is inconclusive. (3,33,34)
Aside from CC, infection around a prosthetic device can cause several issues,
including a superficial cellulitis, chronic wounds, implant failure, and sepsis, indicating
the great importance of maintaining a sterile field and minimizing any potential sources
of contamination. (7,32) Another important risk factor to consider in the reconstructive
and cancer population, is adjuvant radiation therapy. Radiation poses an increased risk for
a patient developing CC, with a rate up to 30%. (33) This is due to the increased amount
of fibrosis, which, would also affect the capsule around the implant. It is, therefore, a
relative contraindication for patients receiving implant-based augmentation. (33) The
staging of procedures, as mentioned above, or the use of autologous methods of
augmentation are recommended. (3,7)
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1.2.5

Breast Implant Sickness and Lymphoma
Breast Implant Sickness (BIS) or illness (BII) have been described since the

1960s. It was first described as Human adjuvant disease (1964), then renamed siliconeinduced human adjuvant disease in 2011, then silicone implant incompatibility syndrome
in 2013, and is now known as BIS or BII. (35) BIS is an assumed autoimmune disease
that arises after the surgical implantation of a silicone prosthesis in the breast. (35) A
large part of BIS is yet to be fully understood. The presenting symptoms are extensive
and non-specific, some of the most reported symptoms include, fatigue, muscle pain,
headaches, hair loss, dry mucous membranes, poor memory, depression, and anxiety. The
current treatment recommendation is implant and capsule removal. In most cases, surgery
has resulted in the resolution of patient symptoms. (35)
The literature describes a second, more serious disease in a small subset of
patients who have been exposed to Allergan BIOCELL breast implants being 18 times
(one in 2,832) more likely to develop a condition known as ‘Breast Implant-Associated’
Anaplastic Large Cell Lymphoma (BIA-ALCL), which is a T-cell lymphoma.
(6,35,36,37) This is a systemic cancer which is now understood to be associated
specifically with the BIOCELL implants. Symptoms, are however, more specific, they
include breast enlargement, pain, swelling, hardening, a fluid collection, and possibly
lymph node involvement. These are typically noticed at least one year post-operatively
and on average after 8-10 years. Patients can also experience general B-symptoms
associated with cancer, including fatigue, weight loss and night sweats. (7,36,37)
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If a patient is thought to have BIA-ALCL, this should be worked up, similar to
any other systemic cancer. Initial steps should include diagnostic imaging with a CT
(Computerized tomography) or PET (Positron emission tomography) scan to assess the
extent, and stage the disease. The involvement of an oncology service is strongly
recommended. From a surgical perspective, the removal of the implant, along with the
capsule is recommended. Surveillance with imaging is recommended for two years postimplant removal. Once resolved, disease recurrence has not been documented. (36,37)
Due to this association between textured implants and lymphoma, there has
understandably, been a huge shift from patients to either exchange their current textured
implants or avoid implants altogether. This has not only put pressure on surgeons, to
comply with patient requests, but also manufacturers to subsidize the cost. There has
been extensive litigation over this matter, and the Allergan BIOCELL implant has since
been recalled. Of note, smooth implants, and textured implants from other manufacturers
have not been associated with BIA-ALCL. (36,37)

1.2.6

Summary
The use of breast implants remains the gold standard option in breast

augmentation. The choice of implant, procedure staging, and surgical technique are
important factors every surgeon should consider. Understanding patient goals and
counseling them on expectations, potential complications and anticipated outcomes is
crucial. Despite the popularity of implants, an ever-growing subset of patients are
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requesting a ‘no implant’ augmentation, which has given rise to more autologous
surgeries, most notably, fat grafting.

1.3
1.3.1

Fat Grafting
Cell Biology

White adipose cells are a normal component of the subcutaneous tissue, found all
over the body. The distribution and quantity of adipose cells, varies significantly from
person to person and relies on a multitude of genetic, social, and environmental factors.
(46,48)
Each white adipose cell is composed of mainly lipids (80%), and 90% of the lipid
component is made up of six triglycerides (linoleic, myristic, oleic, palmitic, palmitoleic
and stearic acid). The remainder of the adipose cell is made up of cholesterol, free fatty
acids, mono- and di- glycerides. Each cell contains a large central vacuole, as this
expands to accommodate the above contents, the cell nucleus and organelles are pushed
to the periphery. This gives adipose cells the classical ‘signet ring’ appearance under the
microscope. The size of each individual cell varies from 30 to 230 microns. (46,47,48)
Adipose cells, and in turn fat, are the main energy reservoir in humans. Fat is mainly
derived from excess consumption in an individual’s diet. Foods high in lipid content,
provide lipids that are easily used or stored. Other nutrients, in excess, such as
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carbohydrates and proteins, can undergo a conversion in the liver to fat for storage.
(46,48)
Historically, fat was only considered useful for insulation, energy storage, thermal
regulation, and mechanical protection. However, fat is much more complex, participating
in a multitude of interactions with the cardiovascular, endocrine, and neurovascular
systems. Fat is composed of both adipose and stromal cells, which most notably include
adipose tissue-derived stem cells (ADSCs). ADSCs have the ability to differentiate into
cells with a mesenchymal origin, such as chondrocytes, osteocytes, myocytes and in the
case of fat grafting, adipocytes. The conversion of ADSCs to adipocytes is known as
adipogenesis, which is a normally occurring process to increase the amount of fat, when
current stores are insufficient. This process is quite sensitive and certain factors such as
radiation, not only significantly dampen the proliferative abilities of ADSCs but also
increase local apoptotic cells, causing fat loss. (46,47,48)

1.3.2

Historical Overview
Autologous fat grafting (AFG) was first described in 1893 by Neuber as a method

of reconstructing soft tissue defects. (42) In 1919 and 1920, the first textbooks describing
fat grafting to the breast were published by Lexer and Pennisi, respectively. A landmark
paper published by Mel Bircoll in 1987 described his long experience with fat grafting,
despite his early success with fat grafting, the calcific nodules (which is caused as a result
of fat necrosis) raised concern, as radiological imaging at the time, was not able to
differentiate calcific nodules caused by fat necrosis and cancerous lesions with certainty.
This raised oncological concerns with the procedure and that same year, the American
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society of plastic surgeons (ASPS) took an unprecedented stance and banned fat grafting
to the breast for the next two decades. (42)
In 2001, Sydney R. Coleman published his methods of fat grafting, which have
since been termed, ‘the Coleman technique’, this was centered around the gentle handling
of fat to improve the purification of alive adipocytes. Multiple other publications and
clinical trials followed over the next several years. Following the overwhelming data on
efficacy and safety, the ASPS reversed its decision on fat grafting to the breast in 2009,
declaring it “effective with no significant risk”. (42,43,44) Today, fat grafting is an
incredibly popular technique used by plastic surgeon to correct defects and augment
volume in any part of the body. More so, data over the past decade has emphasized the
safety and effectiveness of the procedure (43,44,45)

1.3.3

Pathophysiology
Autologous fat grafting (AFG) consists of three main steps. Liposuction of the fat

from areas of excess, processing of the harvested fat, and re-injection of the processed fat
into the desired region. Common areas of harvest include the abdomen, flanks, and
thighs, as they are common areas of excess. AFG involves the avascular transfer of fat;
therefore, the donor cells must revascularize from the surrounding tissue to survive. (46)
Currently, there are three main theories of fat graft survival after avascular implantation.
First, Peer et al. described their theory of graft survival, which hypothesizes that
grafts survive differently in the short and long term. Initially, the avascular, grafted fat
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survives by diffusion, through the direct contact with the surrounding vascularized tissue.
Later, the fat stimulates an inflammatory reaction, which in turn stimulates a molecular
cascade which initiates vasculogenesis and angiogenesis to support long term survival.
(47) Therefore, smaller volume grafts achieve increased survival as they are better suited
to achieve nutrient supply through complete diffusion until complete neovascularization
occurs. (48) More recently, the graft replacement theory was described, in which very
few grafted adipocytes are thought to survive and instead are replaced by ADSCs that are
transferred with the fat. (49) ADSCs are collected and concentrated intra-operatively.
They are a natural component of lipo-aspirate, in which, using commercially available
devices are concentrated into a serum, which can be added to the harvested fat, for
injection.
As such, recent studies have focused on investigating the enrichment of fat grafts
with ADSCs, as well as stromal vascular fraction (SVF). SVF is a collection of cells
(mesenchymal stem cells, endothelial cells, T-cells, M2 macrophages and preadipocytes),
that are isolated from the lipo-aspirate. They have emerged as a desirable source of cells
with anti-inflammatory and regenerative potential. They have been correlated to
increased graft retention. (49,50)
Lastly, the host replacement theory postulates that no grafted cells survive and
instead necrose and are replaced by new fat cells, fibrous tissue, and new blood vessels.
(49) It is likely that the true mechanism of avascular fat grafting includes aspects from all
three of these theories. The underlying principles of all theories have emphasized the
health of the donor adipose cells with smaller volume grafts, to increase direct contact
with the surrounding vascularized tissue. (48)
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This is encompassed by the three-zone survival theory that states when fat is
transferred, it can be divided into cellular zones. (50,51) As described by the Coleman
technique, the current recommendation is to inject the fat in thin strands, with a fan like
pattern, over multiple sessions to achieve the desired result. This allows for a larger
surface area to be in direct contact with the surrounding vascularized tissue. The injected
fat, as a whole, is divided into zones. The most peripheral zone, which is 0.3 mm thick,
includes cells that directly survive, as they have direct contact with the surrounding
tissue. (51) The middle zone, which is 0.6 mm – 1.2 mm thick, is the regenerative zone,
where ASCs survive and are regenerated into new adipocytes. (50,51) And lastly, the
central zone is known as the necrotic zone, where no cells can survive and are either
resorbed or replaced with fibrotic tissue. (51) The bulk of this process of survival,
neovascularization and regeneration is thought to occur in the first three months;
however, it can take up to a year for the areas of necrosis and fluid to be fully resorbed,
and a stable volume is attained. (46,50)

1.3.4

Retrieval of the fat
Fat harvest involves two steps: first, the injection of tumescent fluid, and second,

liposuction of the fluid and fat from the donor area. Tumescent fluid is a combination of a
crystalloid with low concentrations of epinephrine and lidocaine, which is injected into
the donor area at two to three times the desired extraction volume; the exact formula and
volume are variable depending on surgeon preference. (52,53) This process helps to
develop the adipose plane and decrease blood loss due to vasoconstriction from the
epinephrine. (52) For the purpose of fat grafting, there has been some debate as to the
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effect of lidocaine and epinephrine on fat survival. However, studies conducted on animal
models have shown no effect on fat survival in the use of tumescent fluid versus normal
saline. (54,55) To maximize cell survival, care must be taken in the technique of
harvesting through liposuction. In-vitro studies have found that minimizing cellular
trauma and using larger, blunt-tipped cannulas can increase graft viability. (56,57) Lastly,
utilizing lower pressures during aspiration has been shown to increase adipocyte survival.
(58) Coleman was one of the first surgeons to describe a minimally traumatic technique
using a 3mm blunt-edged two-hole cannula connected to a 10-mL syringe with the
operator manually holding negative pressure. Overall, this knowledge has led to the use
of tumescent fluid, with a small bore blunt-tipped cannula under low-pressure lipoaspiration as the standard method of harvest in AFG procedures. (59)

1.3.5

Fat Processing
Fat processing is a crucial step in AFG that involves techniques to remove as

much fluid, blood, and oil from the aspirated fat before injecting it to the targeted site. If
not removed, these factors can increase inflammation and increase degradation of the fat
graft. (60) The simplest method allows gravity to separate the harvested material and
decant off the liquid component. (61) The Coleman technique involves centrifuging the
fat for 3 minutes at 3000 rpm sterilely to separate the harvested fat from blood,
tumescent, and oil. (62) However, more recent studies have proposed that higher
centrifugal forces can cause damage to fat cells, and lower forces have comparable
outcomes to the decantation method. (63) Fat processing devices have also been
developed in an attempt to refine the fat even further. Many of these devices on the
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market are closed systems that use a combination of gravity and washing. (61) Although
these new devices have shown promising results for decreasing oil, fluid and blood
products while maintaining a high adipocyte viability, there is a lack of clinical data
showing significantly increased retention and survival of cells in the breast once injected.
(59)

1.3.6

Fat injection
In the case of breast augmentation, the target site is the breast, and the fat is

commonly injected in the subcutaneous, pre-pectoral and subpectoral planes to increase
the overall volume of the breast. (59) Based on the principles of fat survival, Coleman
proposed the use of a 17-gauge blunt cannula, injecting small amounts in a retrograde
(Inject while withdrawing the cannula) fashion to decrease trauma and increase surface
area contact with recipient vascular beds. (62) Care must be taken when injecting to do so
in layers, and often surgeons will use a fan-like pattern to avoid creating any larger
pockets of fat graft, which will be more likely to necrose. (57) Furthermore, the volume
of fat injected into the breast should not be overly large for the tissue envelope, which
increases the pressure and can be detrimental to the graft. (46) A recent systematic review
of AFG to the breast showed that the range of injected volume was 20 cc to 607 cc per
session. (70) However, there is no maximum recommended volume of injection, this
varies from person to person and mostly relies on the amount of harvested fat available,
as well as the breasts’ skin laxity and ability to accommodate the volume. Therefore, in
AFG breast augmentation, the increase in size may be limited or require multiple sessions
to achieve the desired effect. (64) However, unlike implant augmentation, the surgeon
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can contour the breasts in a precise fashion to give the patient a more natural shape and
address specific areas of the breast. (62)

1.3.7

Fat Enhancers
In an attempt to increase the volume retained following AFG, in-vitro studies

have evaluated the potential enrichment of fat grafts with a variety of factors, including
SVF, ADSCs, or platelet-rich plasma (PRP). These studies are based on the fat survival
theory that regeneration may play a large role in fat survival. (46) Studies involving
enrichment with ADSCs have shown promising results with 1.5-fold increase in retention
compared to no enrichment. (65) However, enrichment with ADSCs is expensive, and
culturing cells for clinical use is subject to strict regulatory requirements. (66)
Comparatively, SVF cells do not require the same extensive laboratory setup as ADSCs;
however, clinical data has not shown any significant increase in retention compared to
controls. (66) PRP has also been studied as a possible enhancement to AFG. PRP (The
extracted plasma layer from an individual’s blood following centrifugation) contains both
nutrients and growth factors, which could support the graft during the avascular stage and
help to promote neovascularization. (67) Furthermore, compared to ADSCs, it is
relatively easy, safe, and inexpensive. (67) Animal models have shown increased fat
survival when grafts were enriched with PRP; however, clinical data has not shown
significantly increased retention rates. (68,69)
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Fat Grafting Complications

1.3.8
1.3.8.1

Recipient Site

The overall rate of complications after AFG is low regardless of the processing
technique. (70) The most common minor complication is the presence of palpable
nodules in the breast, which is a consequence of necrotic fat (6.2%). (70,71) Other minor
complications include infections (0.85%), cysts (oil, simple) (4.5%), seroma (<0.1%),
granuloma (<0.1%), dysesthesia, lymphadenopathy, pain and hematoma. (70,71,72)
Aesthetic complications may occur as patients weight fluctuates, the grafted fat has
memory, and acts similar to fat from the harvest site. This can lead to the overgrowth or
resorption of fat grafts proportional to the original site. (73,73) Major complications are
defined as complications that require surgical intervention. (71) Additional major
complications include unsatisfactory volume, shape, or breast asymmetry. (71)
Additionally, the greater the volume in the amount of fat injected, the higher the risk of a
patient developing fat necrosis. (70,72) AFG poses a small risk of pneumothorax
(collapse of the lung due to the needle being inserted into the thoracic cavity), fat emboli
(the entry of adipose cells into the vascular system, causing an obstruction) and
septicemia (Contamination of the injected fat, causing a systemic bacterial infection).
(70,71,72)
Lesions such as calcifications and cysts may however complicate breast cancer
screening and follow-up, with possible increased rates of false positives. Follow-up
imaging and/or biopsy for definitive diagnosis is recommended for all palpable breast
nodules. (72) In patients who previously had breast cancer, the rate of re-occurrence
ranges from 0-12%, which is equivalent to the normal population. (70,71)
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1.3.8.2

Donor Site

The site in which the fat is collected, has its own set of surgical complications. Fat
can be harvested from nearly any site of excess. Complications can occur with the
tumescent fluid, during the fat harvest and in the early or late post-operative phase.
Tumescent fluid can vary; however, most published formulations contain lidocaine and
epinephrine, both of which must be calculated pre-operatively to avoid toxicity. If not,
this could lead to cardiac and neurological events, including arrythmias and seizures,
respectively.
As the procedure is performed without direct visualization of the subcutaneous
structures, there is a risk of nerve and vessel damage. If adipose cells enter the vascular
system, this could lead to a fat embolus. More so, in the case of abdominal fat harvests,
intra-abdominal injuries are a possibility. Either from entering the abdominal cavity with
a cannula or injuring an undiagnosed hernial sac. Post-operatively, early complications,
within the first 30 days, include hematoma, seroma, and superficial infections. Later
complications include contour irregularities, skin laxity and dysesthesia.

1.3.9

Fat Survival and Analysis
On average, the post-operative fat loss ranges from 25-70% and only a percentage

of injected fat cells will survive after one year. (75) As mentioned above, fat survivability
is heavily influenced by the harvesting method as any damage to the adipocytes will
reduce the survival rates of the cells. (75,76) It has however been demonstrated that there
is no difference in fat survivability when it is harvested from the abdomen, lateral thigh,
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inner thigh, and flank. (77) In order to promote fat viability, it is best to inject it at a slow
rate to reduce the shear stress. (77,78) To optimize the survivability of the fat, it is best to
place it in areas of high vascularity, typically in the periphery, in a “fanning-out” pattern.
(78,79) Due to the low rates of fat survivability, it may be more beneficial to observe fat
grafting as a percent augmentation versus a percent survival. (79) This would also be
beneficial with patient counselling, advising them that a certain percentage of fat will
survive, therefore, a larger volume would need to be injected, compared to referring to a
specific volume.
The gold standard method for assessing fat viability is histologic analysis to
assess for fibrosis, intact nucleated fat cells, mitochondrial function, and apoptosis. (80)
Magnetic resonance imaging (MRI) can reliably assess breast volume; however, this is
not a cost-effective or time efficient assessment method. (81) The most practical and
validated method currently available to monitor and assess fat survivability is threedimensional (3D) image analysis. (77,82) There are many 3D scanners available, but the
most accurate and reliable tool available to assess breast volume is the VECTRA 3D
imaging system (Canfield, NY, USA). (81)

1.3.10

Future Trends

At present, breast implants remain the primary option for the majority of
augmentations, future trends will need to focus on further improving the physical
implant. Particularly, minimizing the rates of capsular contracture and mitigating any
oncological risk. (83) The focus of new breast implants should also favor optimizing
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minimally invasive surgical techniques and improving patient understanding regarding
recall, replacement, and long-term risks. (83)
In fat grafting, future advancements should focus on reducing inflammation and
improving the design of adipose extraction and processing to ultimately help improve
outcomes and fat survival. (84,85) As fat grafting is also a relatively newer technique
used by this generation of surgeons, there will be a greater shift in helping to clarify
inconsistencies in study results and methodology in human studies, to better understand
ideal patient selection criteria to ensure optimal results in patients seeking fat grafting to
improve previous surgeries as well as those selecting fat grafting as a primary
augmentation method. (85)
With current advances in fat grafting and its current success, it is predicted that fat
grafting could replace the need for implant-based breast augmentation in a significant
subset of the patient population. (86) Fat grafting offers numerous benefits. It’s nonimmunogenic, versatile, bio-compatible, and readily available. More so, it’s relatively
minimally invasive, with no large incisions. (86) Fat grafting advances will also help the
development of other cosmetic procedures as this technique is also currently being used
for facial and body contouring, wound healing, and the treatment of inflammatory
conditions. (87)
At present, fat retention, predictability and analysis remain the most complicated
aspects. It is difficult to guarantee certain volumes post-operatively, however, the
literature has demonstrated that several sessions of fat grafting are safe, if, the above
pathophysiology of fat survival is respected. The first session also demonstrates the
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amount of fat survival to be expected in each patient, allowing for relatively more
predictable future sessions.

1.4

Autologous Breast Reconstruction

A subset of patients undergoing breast augmentation have had previous surgery
due to breast cancer. Patient factors in these circumstances are more nuanced when
assessing the appropriate method of reconstruction and augmentation. Implants and fat
grafting can be used in tandem, initially, to create the optimal size and then contour postoperatively with fat grafting. However, certain patients would not be amenable to
implants or fat grafting, as the tissue loss from cancer is too large and/or patients require
or have received radiation as part of their cancer treatment that has fibrosed the recipient
site and altered the micro-environment, as well as the regional capacity for
neovascularization.
These patients may instead be advised to undergo more elaborate reconstruction
using local, regional, or free flaps to bring healthy, non-radiated tissue into the breast
recipient site as a partial or total replacement of breast tissue. Autologous reconstructions
(to replace partial or total breast volumes lost to cancer surgery) differ from fat grafting
in that the total tissue with its own blood supply is harvested from one site and relocated
to the breast area. While outside of the scope of discussion for this thesis aimed at
evaluating fat grafting techniques, a review of the current gold standard of free flap
reconstruction along with alternatives is attached. (Appendix 1).
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1.5

Conclusion

Currently, patients can choose whether they prefer to receive implant-based or fat
grafting breast augmentation. Patient selection and thorough understanding of both
procedures is critical. Future directives should include focusing on comparing patient
outcomes and satisfaction for patients who undergo implant-based augmentation and fat
grafting. More human studies should focus on improving techniques to optimize fat
retention and survival factors. This will allow for the implementation of best-practice
guidelines regarding patient selection and operative techniques for fat grafting.
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Fat Grafting vs. Implants: Who’s Happier? A systematic
review and meta-analysis

2

This chapter is an altered version of a manuscript pending submission to the plastic
and reconstructive surgery journal (PRS). Following from the above chapter, the review
addresses the two common methods of breast augmentation from the patient’s
perspective. To date, this is the most comprehensive qualitative meta-analysis assessing
primary breast augmentation.

2.1
2.1.1

Background
Breast Augmentation

Breast implants were first introduced in the 1960s in Texas and have long
been used for reconstructive and cosmetic surgery and have since created a multimillion-dollar industry. (1,2,3,4) Breast implants are the most common mode for
breast reconstruction and accounted for 72.3% of breast augmentation procedures in
2016. (5) Breast implants now come in many different shapes, sizes, and materials for
patients to achieve the best possible result based on their wants and needs. (2,6)
Implant-based breast procedures carry several risks of complications, including
capsular contracture, breast animation, implant failure, breast implant-associated
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anaplastic large cell lymphoma (BIA-ALCL), and possible consequences to
psychological well-being. (4,5,6)
Fat grafting, otherwise known as fat transfer, lipoagumentation, liposculpture,
or lipomodeling, has created a shift in the field of plastic and reconstructive surgery in
the approach to patient care. (4,7) Fat grafting was first introduced in 1897 by Czerny
for reconstructive surgery. (7) In 1987, the American Society of Plastic Surgeons
condemned fat grafting procedures with concerns for oncological safety but have
since been proven to have no additional risk, and in 2009, fat grafting was revisited
and approved as a technique that could be used in plastic and reconstructive surgery.
(1,8) Since the year 2000, fat grafting accounts for a 29% increase in breast
reconstruction and a 25% increase in cosmetic breast surgery. (1) In cosmetic surgery
for primary augmentation, it provides an advantage of breast augmentation without a
prosthetic device which eliminates the possibility for rippling and other cosmetic
concerns and complications seen with breast implants. (1,4) This procedure is best
suited to patients who would like a moderate increase in their breast volume, typically
seen in patients who underwent significant weight loss or post-pregnancy or in
reconstructive patients such as in post-breast cancer reconstructive surgery.

2.1.2

Patient reported outcome measures (PROM)
In cosmetic and reconstructive patients, it is important to assess a patient’s

perception of their quality of life (QoL) to determine the impact on a patient’s
appearance, functional and mental health. (9) By assessing QoL in patients in a valid,
systematic, and reliable way, it can help influence future decision-making for patients
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and physicians. (10) However, when using the patient’s perspective on their quality of
life and outcomes, it is subjected to many biases, and the response rate can be heavily
influenced by motivation, health, age, and socioeconomic status. (11)
The importance of PROMs, particularly in the field of plastic and
reconstructive surgery, where we aim improve form, just as much as function cannot
be overstated. A patient will, in most cases, negate the surgical results if their quality
of life remains poor. PROMs can be broken down by generic, specialty, or procedure
specific. A 2019 review by Sharma et al. highlighted the currently available
instruments available to assess PROMs in plastic and reconstructive surgery. For the
breast, they highlighted three instruments. BreastQ, Breast evaluation questionnaire
(BEQ) and Breast reduction assessed severity scale questionnaire (BRASSQ). Of
note, BreastQ and BEQ are the only two breast specific instruments that are validated
to assess breast augmentation. They concluded that BreastQ is currently the most
well-validated breast specific PROM instrument available, with the added benefit of
having a pre-operative and post-operative component.

2.1.3

BreastQ
BREAST-Q is an example of a patient-reported outcome measure (PROM) as

it is a standardized form completed by patients. (9) The BREAST-Q questionnaire
was developed in 2009 and can be used for various cohorts of patients, including
augmentation, reduction, and reconstructive patients. It aims to investigate topics
known as modules such as psychosocial, physical, sexual well-being, satisfaction of
care, and satisfaction of breasts. (9,10,12) Since its introduction, BREAST-Q has
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become the gold standard for assessing quality of life and patient satisfaction for
patients undergoing breast surgery. (12) (Appendix 4)
The BREAST-Q module for women who undergo breast augmentation is a
rigorously developed PROM that is comprised of 9 independently functioning scales.
(9) It has undergone extensive psychometric evaluation and its developers report that
it may be used like interval-scale data. Scores from these instruments are scaled to
range from 0 to 100.
This review aims to highlight the importance of PROMs when considering
various surgeries. There have been several observational and assessment tools to
compare cosmetic outcomes. However, to use a relatively objective scale to assess
how satisfied a person is with their initial objective, in this case augmentation, is
valuable. The use of blinded surgeons to evaluate before and after images only gives
us one perspective. Arguably, a surgeon’s visual assessment of an outcome is
important, however, as surgeons, we are sometimes biased with varying levels of
expectations post-operatively compared to patients.
The main outcome in this study is PROMs using BREAST-Q. This systematic
review and meta-analysis aim to compare patients ’quality of life outcomes using
BREAST-Q to assess if patients who undergo fat grafting or implant-based primary

augmentations are more satisfied.
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2.2
2.2.1

Methods
Search Strategy

Prior to commencing the review, the PROSPERO database was searched, and no
similar review was found. The study methodology was then designed and was registered
in the PROSPERO database (CRD42022297860). The Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guideline was used (Appendix 2).
The search strategy was designed by the lead author and two reviewers (K.M. and K. J.).
The search strategy included search terms related to primary breast augmentation, the two
methods of interest, and terms related to the primary outcome, Breast-Q. The full search
strategy, including terms used can be seen in Appendix 2.
Five bibliographic databases were searched: PubMed®, Cochrane Library®,
EMBASE®, MEDLINE® and Scopus ®. The search was conducted on November 4,
2021. References were manually screened by the lead author and two reviewers from
relevant review articles to identify if there were any studies that were not captured in the
initial search. However, no additional sources were identified in this process.

2.2.2

Inclusion and Exclusion Criteria
Inclusion and exclusion criteria were determined a priori. We included

prospective studies, retrospective studies and randomized controlled trials written in
English or French, published in peer reviewed journals over the past ten years from
the date of the search. As autologous fat grafting was approved in 2009, a range from
2011-2021 would allow us to capture similar data from both groups. Only studies that
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included patients who underwent primary breast augmentation using either implants
or fat grafting for aesthetic purposes were included. Studies reporting on
augmentation with a combination of implant and fat grafting, or breast reconstruction
were excluded. Patients who have had a previous mastectomy were excluded due to
them having undergone a previous breast surgery which may skew their score. We
excluded patients undergoing gender affirmation surgery as they would be unable to
complete the pre-operative BreastQ survey. Patients who have had massive weight
loss have been excluded from the study as their surgeries are multifactorial and would
not be eligible for fat grafting as they would typically require skin removal. We
excluded patients who have had multiple sessions of fat grafting, as we are assessing
the primary surgery in this review. All studies must report at minimum post-operative
Breast-Q data as a study outcome to be included. Single case reports, reviews, animal
studies, conference proceedings, abstracts, inaccessible manuscripts, editorials and
articles not reporting BreastQ were excluded. (Table 1).
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Parameters

Inclusion

Exclusion

Journal
Characteristics

Prospective,
Retrospective or
Randomized
controlled trial
Peer Reviewed
English

Editorial, Case
Report, Abstract,
Presentation, Poster
Non-Peer Reviewed
Non-English
Published prior to
2011

Sample
characteristics

Human
N >1
Primary breast
augmentation
patients

Non-human
Breast
Reconstruction
patients
(mastectomy)
Gender
confirmation
surgery
Massive weight loss

Methods

Primary Implant
augmentation (Any
type of implant)
Primary fat grafting
augmentation

Combination
implant and fat
grafting
augmentation
Revision of
previous
augmentation (ex.
Implant exchange,
implant removal
and fat grafting,
secondary fat
grafting session)

Outcomes

Primary: BREAST-Q
Secondary: common
complications
• Fat necrosis
• Implant rupture
• Hematoma
• Seroma
• Infection

Does not report
BREAST-Q

Table 1. Inclusion and Exclusion Criteria.
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2.2.3

Study Selection
Studies extracted were analyzed, and duplicates were eliminated. The primary

investigator extracted the studies which then underwent screening by two independent
reviewers (K.J. and K.M.) using Rayyaan platform to organize and manage the
articles for a systematic review (Rayyaan Systems Inc., Cambridge, MA, USA). For
the primary screen, titles and abstracts were reviewed. Selected articles underwent

full-text review for the secondary screening. The principal investigator functioned as
an independent arbitrator (K.A.) and was available for any conflict disputes. The
Methodological Index for Non-Randomized studies (MINORS) score was used to
assess the quality of all articles selected for the review and meta-analysis. Papers that
failed to achieve a benchmark score of 60% or higher were excluded. (Appendix 2)

2.2.4

Data Extraction
The two independent reviewers (K.J and K.M) extracted data using the Google

Sheet platform (Google, Mountain View, CA, USA). Any possible errors were
reviewed and discussed with the principal investigator (KA) to ensure correctness.
Study type, number of patients, average age and BMI, type of augmentation,
augmentation characteristics and surgical technique, pre- and post-operative Breast-Q
data, and common complication rates were extracted. Attempts were made to contact
the authors of any study that had incomplete Breast-Q data or mentioned conducting
Breast-Q but where the Breast-Q data was not reported in their paper.
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2.2.5

Statistical analysis
Statistical and meta-analysis was conducted by a contracted statistician.

Cohen’s kappa coefficient was calculated to assess for inter-rater reliability for article
selection, with values 0.41-0.60, 0.61-0.80 and 0.81-1.00 representing moderate
agreement, substantial agreement, and perfect agreement respectively. Studies that
reported multiple patient groups using the same augmentation technique were pooled

to create a single summary for that study.
Mean scores from the Breast-Q instruments were meta-analyzed using
random-effects models with the empirical Bayes between-study variance estimator.13
As pre-operative scores were not consistently available, the primary outcome measure
was the post-operative mean Breast-Q score, and whether the pooled average was
different between breast augmentation methods, either using implants or fat grafting.

Therefore, post-op mean scores were stratified by surgical method as the main factor
of interest. Inferences about the differences in pooled subgroup means were
performed using meta-regression, which is well-known as a form of subgroup
analysis. Reported demographics in the pre-op period (age, BMI) were used to
explore possible sources of heterogeneity by meta-regression.
Between-group heterogeneity was characterized using the random-effects
heterogeneity parameter (τ²), and I2, which describe the absolute or relative degree of
between-study heterogeneity. For the meta-regression models, the adjusted R2 statistic
was used to assess the proportion of variance between studies, which could be
attributed to the covariates. Publication bias was assessed by funnel plots, as well as
Egger’s regression test. Galbraith plots (also known as radial plots) with the same
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random-effects model were assessed to examine between-study heterogeneity and to
identify potential outlier studies.
Bivariate meta-regression of scores were used to corroborate whether and to
what extent were potential differences in pooled estimates of post-op scores between
surgical methods confounded by the few available pre-op scores. These models
included surgical method as the only factor and were fit using a random-effects model
restricted maximum likelihood estimator. A conservative value of 0.2 was assumed
for the within-study correlation between pre-op and post-op scores.
All analyses were performed in Stata 17 (StataCorp LLC, College Station, TX).

2.3
2.3.1

Results
Study Characteristics

The search strategy identified a total of 1398 articles and an additional 5 were
added from relevant reviews discovered in the search. After duplicates were removed, a
total of 597 articles were screened using title and abstract. A total of 57 articles were
selected for full text review, and 22 fit the inclusion criteria and were deemed suitable by
both reviewers and independent arbitrator for data extraction. The Cohen’s Kappa scores
were 0.87 for primary screen and 0.88 for secondary screen. All studies included
received a MINORS Score of 60% or higher. Of these 22 studies, 14 included data that
could be pooled for a meta-analysis, which included two fat grafting studies, ten implant
studies and two studies that included data from both methods (Figure 1). Total number of
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patients included in this study was 1616, with 81 in the fat grafting group and 1535 in the
implant group.

2.3.2

Post-operative satisfaction score
Two small studies (Brault and Tenna) reported on both fat grafting and implant

augmentation methods. The mean satisfaction score for implants was 12.9 points greater
than with fat grafting (95% CI: -0.6, 26.5, p=0.061; Figure 1), with only moderate
heterogeneity (Q=2.68, p=0.11).

Fat grafting

Implant

Post-op score
Study label

Size (N) mean (SD)

Post-op score
Size (N) mean (SD)

Brault (2017) 22

71.4 (21.8)

15

51.6 (8.6)

Tenna (2017) 22

78.0 (22.0)

16

72.0 (11.0)

Table 2. Studies comparing satisfaction scores for both augmentation methods (N=2)
Abbreviations: SD, standard deviation
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Figure 1. Forest plot of mean difference in post-op satisfaction score between
augmentation methods.

There were 14 studies that reported post-operative satisfaction scores that could
be pooled, and infrequently reported pre-op scores (Table 3). Mean post-op scores were
pooled for each method of augmentation, and overall (Figure 2) there was no evidence of
publication or small study bias, but the relative heterogeneity within augmentation groups
was high.
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Study

Method

Size (N) Pre-op score Post-op score
mean (SD)

mean (SD)

Overschmidt (2018) Implant

72

20.6 (15.1)

85.3 (12.3)

Overschmidt (2018) Implant

13

19.3 (18.2)

87.2 (14.1)

Randquist (2018)

Implant

22

n.r.

69.2 (14.8)

Guo (2019)

Fat grafting 8

16.8 (16.5)

50.4 (16.6)

Xu (2006)

Implant

70

14.7 (11.0)

64.9 (5.6)

Deschler (2020)

Fat grafting 42

23.8 (20.8)

62.8 (13.3)

Diaz (2017)

Implant

150

n.r.

80.6 (15.1)

McCarthy (2012)

Implant

41

27.0 (18.0)

70.0 (23.0)

Bracaglia (2020)

Implant

70

29.6 (13.3)

85.5 (6.6)

Xiao (2020)

Implant

57

30.3 (6.1)

55.8 (7.8)

Xiao (2020)

Implant

66

29.6 (6.3)

55.4 (8.6)

Gryskiewicz (2014)

Implant

670

n.r.

76.0 (16.6)

Faure (2021)

Implant

40

n.r.

71.8 (18.5)

Li (2021)

Implant

65

22.5 (12.1)

76.6 (11.8)

Li (2021)

Implant

155

16.1 (10.3)

60.8 (19.3)

Brault (2017)

Fat grafting 15

n.r.

51.6 (8.6)

Brault (2017)

Implant

22

n.r.

71.4 (21.8)

Tenna (2017)

Fat grafting 16

n.r.

72.0 (11.0)

Tenna (2017)

Implant

n.r.

78.0 (22.0)

22

Table 3. Reported Pre-op and post-op satisfaction scores (N=14 studies)
Abbreviations: n.r., not reported; SD, standard deviation
For analysis, groups were pooled within studies if the same augmentation method was
used.
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Figure 2. Forest plot of post-op satisfaction scores, stratified by augmentation
method (raw mean).
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The pooled mean in the implant group is statistically greater than in the fat
grafting group (Figure 2). Based on meta-regression, the estimated difference in mean
post-op satisfaction scores is 13.0 (95% CI: 2.4 to 23.5; p=0.016). Augmentation method
explained 26.4% of observed variation.

Factor

Studies Mean

Age, mean

13

BMI, mean 8

95% CI

p-value R² (%) I² (%)

0.86

(-0.15, 1.86) 0.094

14.2

97.7

2.83

(-1.02, 6.68) 0.149

14.5

97.9

Table 4. Univariable meta-regression of post-op satisfaction score on baseline
characteristics.

Table 4 shows univariable meta-regression of post-op satisfaction scores on mean
post-op age and BMI. Despite some studies failing to report demographic details, both
age and BMI were strongly associated with greater post-op satisfaction scores. Both
factors explained about 20% of observed variation among the subset of reporting studies.
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Factor

Mean

95% CI

p-value

Implant method

10.45

(-5.59, 26.49) 0.202

Age, mean

1.01

(-0.32, 2.35)

0.137

BMI, mean

3.51

(0.16, 6.87)

0.040

Joint test of coefficients, p-value

0.044

80.36
R² (%)

45.7

I² (%)

94.3

Studies

8

Table 5. Multivariable meta-regression of post-op satisfaction score.

Meta-regression of post-op scores on age, BMI and method substantially reduced
the between-study heterogeneity parameter (τ²), reduced (I²), and increased the proportion
of explained variance (R²). The implant method is still associated with a greater score
than fat grafting after adjusting for age and BMI. Overall, these three factors appear to
account for much of the between-study heterogeneity (Table 5).
To support the claim that differences in post-op mean scores between methods are
not confounded by pre-op scores, a bivariate meta-regression was conducted to account
for pre-op scores, using method as the only covariate. Using bivariate meta-regression,
the mean change in the implant group was grater in magnitude, but not statistically
significant, from the change in the fat grafting group 12.4 (95% CI: -4.9 to 29.6;
p=0.160). That this difference was similar in magnitude corroborates that pre-op scores
did not differ between groups. Following bivariate meta-analysis, heterogeneity was
reduced in post-op scores (I²=74.4%).
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2.3.3

Post-operative sexual well-being score
Two small studies reported on both fat grafting and implant augmentation

methods (Table 6). The mean sexual well-being score was similar in both implant and fat
grafting groups (difference = -0.4, 95% CI: -16.9, 16.0, p=0.96; Figure 3), with moderate
heterogeneity (Q=3.41, p=0.06).

Fat grafting

Implant

Post-op score
Study label

Size (N) mean (SD)

Post-op score
Size (N) mean (SD)

Brault (2017) 22

65.7 (24.4)

15

56.8 (19.3)

Tenna (2017) 22

74.0 (14.0)

16

82.0 (18.0)

Table 6. Studies comparing sexual well-being scores for both augmentation methods
(N=2)
Abbreviations: SD, standard deviation

Figure 3. Forest plot of mean difference in post-op sexual well-being score between
augmentation methods.
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There were 13 studies that reported post-operative sexual well-being scores that
could be pooled (Table 7). Mean post-op scores were pooled for each method of
augmentation, and overall (Figure 4). There was no evidence of publication or small
study bias, but the relative heterogeneity within augmentation groups was high.

Study

Method

Size (N) Post-op score Post-op score
mean (SD)

mean (SD)

Overschmidt (2018) Implant

13

36.2 (20.8)

95.1 (7.8)

Overschmidt (2018) Implant

72

36.7 (18.2)

90.4 (13.5)

Randquist (2018)

Implant

22

n.r.

80.0 (22.7)

Guo (2019)

Fat grafting 8

25.6 (16.9)

75.4 (12.3)

Xu (2006)

Implant

16.1 (9.3)

83.9 (8.5)

Deschler (2020)

Fat grafting 42

40.4 (18.0)

57.1 (17.6)

Diaz (2017)

Implant

150

n.r.

88.0 (17.8)

McCarthy (2012)

Implant

41

35.0 (19.0)

72.0 (29.0)

Bracaglia (2020)

Implant

70

35.4 (25.7)

91.6 (6.5)

Xiao (2020)

Implant

66

35.6 (6.7)

51.0 (8.3)

Xiao (2020)

Implant

57

36.2 (8.8)

52.8 (9.3)

Faure (2021)

Implant

40

n.r.

62.4 (17.4)

Li (2021)

Implant

65

29.4 (9.7)

61.5 (14.6)

Li (2021)

Implant

155

30.5 (10.4)

62.4 (25.5)

Brault (2017)

Fat grafting 15

n.r.

56.8 (19.3)

Brault (2017)

Implant

22

n.r.

65.7 (24.4)

Tenna (2017)

Fat grafting 16

n.r.

82.0 (18.0)

Tenna (2017)

Implant

n.r.

74.0 (14.0)

70

22

Table 7. Reported Pre-op and post-op sexual well-being scores (N=13 studies)
Abbreviations: n.r., not reported; SD, standard deviation
For analysis, groups were pooled within studies if the same augmentation method was
used.
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Figure 4. Forest plot of post-op sexual well-being scores, stratified by augmentation
method (raw mean).
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2.3.4

Post-operative psychosocial well-being score
Two small studies reported on both fat grafting and implant augmentation

methods (Table 8). The mean sexual well-being score was similar in both implant and fat
grafting groups (difference = -2.8, 95% CI: -3.1, 8.6, p=0.35; Figure 5), with no
heterogeneity (Q=0.96, p=0.33).

Fat grafting

Implant

Post-op score
Study label

Size (N) mean (SD)

Post-op score
Size (N) mean (SD)

Brault (2017) 22

63.0 (22.8)

15

67.2 (23.4)

Tenna (2017) 22

83.0 (8.0)

16

79.0 (12.0)

Table 8. Studies comparing sexual well-being scores for both augmentation methods
(N=2)
Abbreviations: SD, standard deviation

Figure 5. Forest plot of mean difference in post-op psychosocial well-being score
between augmentation methods.
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There were 13 studies that reported post-operative sexual well-being scores that
could be pooled (Table 9). Mean post-op scores were pooled for each method of
augmentation, and overall (Figure 6).

Study

Method

Size (N) Post-op score Post-op score
mean (SD)

mean (SD)

Overschmidt (2018) Implant

72

49.5 (18.1)

91.0 (12.9)

Overschmidt (2018) Implant

13

48.2 (14.1)

93.2 (12.7)

Randquist (2018)

Implant

22

n.r.

84.0 (21.0)

Guo (2019)

Fat grafting 8

37.1 (12.7)

55.1 (11.7)

Xu (2006)

Implant

70

10.2 (13.1)

78.9 (10.1)

Deschler (2020)

Fat grafting 42

43.1 (22.8)

63.5 (16.4)

Diaz (2017)

Implant

150

n.r.

89.1 (16.5)

McCarthy (2012)

Implant

41

45.0 (19.0)

78.0 (24.0)

Bracaglia (2020)

Implant

70

44.3 (10.9)

89.9 (8.7)

Xiao (2020)

Implant

57

36.5 (5.1)

48.5 (9.2)

Xiao (2020)

Implant

66

35.8 (5.5)

47.4 (6.9)

Faure (2021)

Implant

40

n.r.

64.7 (16.7)

Li (2021)

Implant

65

40.7 (13.4)

67.6 (17.8)

Li (2021)

Implant

155

41.4 (14.1)

71.9 (21.0)

Brault (2017)

Fat grafting 15

n.r.

67.2 (23.4)

Brault (2017)

Implant

22

n.r.

63.0 (22.8)

Tenna (2017)

Fat grafting 16

n.r.

79.0 (12.0)

Tenna (2017)

Implant

n.r.

83.0 (8.0)

22

Table 9. Reported Pre-op and post-op psychosocial well-being scores (N=13 studies)
Abbreviations: n.r., not reported; SD, standard deviation
For analysis, groups were pooled within studies if the same augmentation method was
used.
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Figure 6. Forest plot of post-op psychosocial well-being scores, stratified by
augmentation method (raw mean).

The pooled mean in the implant group showed no statistically significant
difference than in the fat grafting group (Figure 6). Based on meta-regression, the
estimated difference in mean post-op psychosocial well-being scores is 10.1 (95% CI: 4.8 to 25.1; p=0.184). Augmentation method explained 5.4% of observed variation. The
study by Xiao et al (2020) is an apparent outlier based on a Galbraith plot. Excluding this
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study resulted in a more precise estimate of the difference between methods, in which the
average implant group had a significantly higher score than fat grafting by 13.1 (95% CI:
1.2 to 25.1; p=0.031). The variation explained by method also increased to 24.1%.

Factor

Studies Mean

Age, mean

11

BMI, mean 7

95% CI

p-value R² (%) I² (%)

1.49

(0.57, 2.41)

0.001

-0.24

(-5.81, 5.32) 0.931

52.1

89.4

0.0

97.9

Table 10. Univariable meta-regression of post-op psychosocial well-being score on
baseline characteristics. * Excluding the study by Xiao (2020).

Table 10 shows univariable meta-regression of post-op psychosocial well-being
scores on mean pre-op sex and BMI. Despite some studies failing to report demographic
details, both age and BMI were strongly associated with greater post-op psychosocial
well-being scores. Both factors explained about 20% of observed variation among the
subset of reporting studies.
Factor

Mean

Implant method

12.13

(2.19, 22.06) 0.017

Age, mean

1.25

(0.48, 2.03)

Joint test of coefficients, p-value

95% CI

p-value

0.002
0.000

36.93
R² (%)

71.4

I² (%)

82.9

Studies

11

Table 11. Multivariable meta-regression of post-op satisfaction score.
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Meta-regression of post-op scores on age and method substantially reduced the
between-study heterogeneity parameter (τ²), reduced (I²), and increased the proportion of
explained variance (R²). BMI was not associated with post-op score in univariate
regression and was not included in this model. The implant method is still associated with
a greater score than fat grafting after adjusting for age, and excluding the single outlier
study by Xiao (2020) (Table 11)

2.3.5

Post-operative physical well-being score
There were no studies that provide direct comparison of the physical well-being

scores. There were 8 studies that reported post-operative sexual well-being scores that
could be pooled (Table 12). Mean post-op scores were pooled for each method of
augmentation, and overall (Figure 7).
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Study

Method

Size (N) Post-op score Post-op score
mean (SD)

mean (SD)

Randquist (2018) Implant

22

n.r.

86.1 (13.4)

Xu (2006)

Implant

70

87.1 (10.4)

85.2 (11.7)

Deschler (2020)

Fat grafting 42

90.1 (15.0)

90.4 (10.6)

Diaz (2017)

Implant

150

n.r.

86.7 (13.5)

Bracaglia (2020)

Implant

70

92.1 (10.2)

89.9 (9.0)

Xiao (2020)

Implant

57

92.8 (6.7)

92.8 (8.0)

Xiao (2020)

Implant

66

93.1 (7.1)

92.4 (7.0)

Faure (2021)

Implant

40

n.r.

22.9 (17.1)

Brault (2017)

Fat grafting 15

n.r.

85.6 (12.2)

Brault (2017)

Implant

n.r.

79.9 (20.1)

22

Table 12. Reported Pre-op and post-op physical well-being scores (N=8 studies)
Abbreviations: n.r., not reported; SD, standard deviation
For analysis, groups were pooled within studies if the same augmentation method was
used.

The pooled mean in the implant group showed no statistically significant
difference compared to the fat grafting group (Figure 7). Based on meta-regression, the
estimated difference in mean post-op physical well-being scores is -10.4 (95% CI: -46.0
to 25.3; p=0.569).
The study by Faure et al (2021) was identified as an outlier based on Galbraith
and funnel plots. Excluding this study resulted in making estimates of mean scores in
each augmentation group more similar, with a difference in means of -1.0 (95% CI: -7.2
to 5.3; p=0.762) (Figure 8).
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Figure 7. Forest plot of post-op physical well-being scores, stratified by augmentation
method (raw mean).
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Figure 8. Forest plot of post-op physical well-being scores, stratified by augmentation
method (raw mean), excluding outlier.
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2.4

Discussion
BREAST-Q is a validated tool that can be used to evaluate patient-reported

QoL in post-operative breast augmentation patients. (17) This meta-analysis
investigated the QoL using BREAST-Q in patients who underwent cosmetic breast
augmentation with either fat grafting or breast implants. To our knowledge, there has
been no other study that compared breast augmentation using breast implants

exclusively or exclusively fat grafting for cosmetic breast augmentation.
Overall, in this review the results demonstrated that patients who received implantbased breast augmentation reported a higher overall satisfaction score than those who
received fat grafting. The results show no difference amongst both groups in terms of
sexual well-being, physical well-being, and psychosocial well-being scores in the
BREAST-Q modules. One possible explanation for the higher overall satisfaction, is

that implant augmentation is one of the most common cosmetic procedures, and
surgeons have developed standardized methods to give an overall more reliable and
predictable result in size and shape of the breasts, leading to increased satisfaction.
(18) In comparison, fat grafting for breast augmentation, is a much newer procedure,
and lacks standardized surgical methods. The major limitations of fat grafting are the
limit of volume increase that can be reliably achieved, and the degree of fat

resorption, which can be up to 60% of fat injected. (19) However, there are
advantages, as the lack of a foreign body may decrease long term complication rates,
and re-operation rates. (20) More long-term follow-up studies are needed to determine
the satisfaction of patients over their lifetime post-augmentation.
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In this study, there were two major outliers. One implant study reported
lower physical well-being scores; this is likely because it was a tuberous breast study
(Faure et al., 2021). A possible explanation of these results is that patients who
undergo breast augmentation with tuberous breasts, who sometimes require several
surgical procedures during their primary procedure, often suffer from physical postoperative symptoms including bruising and swelling, which may impact patient
quality of life. (21) The second outlier was in the psychosocial well-being scores with
a study from the implant group (Xiao et al., 2020). This study was conducted in China
and may demonstrate cultural differences in what different groups define as
psychosocial well-being. BREAST-Q was originally written in English with
standardized questions and has since been translated to many languages to eliminate
the need for patients to be English-speaking. Another limitation with the BREAST-Q
is that it was created in North America and with each translation, the questionnaire is
not adapted to accommodate for cultural differences thus creating a bias to the
Western societies. Therefore, this study as an outlier may be more reflective of the
need to not only ensure adequate translation of the modules but also to ensure that the
modules are adapted to account for cultural differences when being disseminated to
patients outside of North America.

It is difficult to answer the question “who is happier?” when comparing
patients who underwent cosmetic fat grafting and those who received implant-based
breast augmentation. There were very few differences between the groups, and solely
due to the overall satisfaction score being slightly higher in the implant group does
not mean that all patients will be happier in all aspects of their life receiving implant-
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based breast augmentation. Therefore, the external validity of this study cannot be
certain based on the results of this systematic review. In addition, based on the lack of
demographic data, it is uncertain if patients of all ages, BMI ranges, socioeconomic
statuses, ethnic backgrounds, and other demographic characteristics were represented
in this data; therefore, this data may not apply to all populations. (23)
In the context of the current practice, most breast augmentation is implantbased augmentation, which explains why more studies are focused on breast implants.
(5) Worldwide, there is also significant variability in terms of surgical techniques and
types and shapes of implants used, leading to a lack of standardization when using
studies from around the world. (24) Additionally, fat grafting is not as common
worldwide as it is in North America and is specifically not used very frequently in
Latin America and Asia due to concerns about cost, safety, and the possibility of
needing further procedures. (24)
This study included data from 1616 patients and 14 studies; 2 of those studies
investigated fat grafting, 10 investigated implants, and 2 investigated both. This study
has several limitations. There was a lack of randomized control studies, likely due to
the challenges with ethical and logistical concerns patients receiving cosmetic breast
augmentation. (25) Additionally, there was a lack of standardization between each

paper. Not all studies reported both pre-operative and post-operative BREAST-Q
data, and there was variable reliability in reporting this data, although our analysis
revealed there was not an association between pre- and post-operative scores. Many
articles did not provide extensive demographic data, which posed a challenge in
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comparing the studies. Finally, there was a small sample size of patients, and there
were more papers in the implant group than in the fat grafting group.
Our study selection was blinded to help minimize potential biases. However,
none of the contacted authors replied with their BREAST-Q data, which may
introduce presence of publication bias in this study. As the included studies were
primary studies, there is a potential risk of bias; however, all the papers received a
passing score based on the MINORS criteria. (26)
In the future, it would be beneficial to investigate other ways to improve fat
grafting techniques and improve outcomes in fat grafting patients. Additionally, larger
studies comparing breast implant patients to fat grafting patients with matched cohort
data would be helpful to draw more accurate conclusions on the true difference in
QoL outcomes between the two groups.

2.4.1

Limitations
Although this study aims to assess patient satisfaction with a similar goal, breast

augmentation. The two surgical methods are incredibly different, with different patient
expectations and goals. The much smaller patient population in the fat grafting group was
a major obstacle in this review. BreastQ is non-specific to breast augmentation, however,
it is the most accurate PROM instrument available, and the data still represents
deficiencies in fat grafting, that need to be addressed.
We did not have enough pre-operative data to accurately measure the change in
breast score across both groups. A bivariate meta regression showed that the difference in
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available pre-operative scores was not statistically significant when assessing method of
breast augmentation.
The studies did not provide sufficient surgical data, regarding implant placement
or fat grafting technique. Patient dissatisfaction with a certain aspect of their care, could
confound their post-operative scoring. Particularly considering that over 10% of patients
in the implant group, will have some form of capsular contracture in the long term.

2.5

Conclusion

Overall, our study represents the first meta-analysis using Breast-Q scores to
compare patient satisfaction with implant versus fat grafting techniques for primary
breast augmentation. We found that there was a mean 13-point higher mean

satisfaction score in the implant group, although there was no statistically significant
difference in the other QoL parameters evaluated by the Breast-Q score. More
research using standardized methodology and longer term follow up is needed to
further characterize patient satisfaction with augmentation method. However,
currently our review suggests, those who undergo implant augmentation are ‘happier’
with their results.

2.6

Future Implications
The above data does show that patients who have undergone fat grafting

augmentation, are still incredibly satisfied with their results. The deficiencies can be
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accounted for by the lack of standardized surgical techniques, as well as PROMs
comparing two widely different surgeries.
A major obstacle to the widespread adoption of fat grafting is standardized
surgical guidelines to help improve fat survival and ultimately, patient outcomes.
Particularly, given the unpredictable percentage of fat survival and need for multiple fat
grafting sessions. The next chapter will outline a proposed clinical trial which is designed
to contrast two common methods of fat processing, to help create more standardized
methods to establish clinical guidelines.
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The fat analysis trial (FAT): A Double Blinded Prospective
Randomized Controlled Trial

3

This chapter is a proposed randomized controlled trial publicly available on
clinicaltrials.gov (NCT05318716) and submitted to the trials journal for publication. With
this trial, the aim is to evaluate methods of processing lipoaspirate, as well as patient
reported outcome measures (PROM), surgical outcomes and fat incorporation.

3.1

Background

Fat grafting is a technique used commonly in plastic surgery that has gained
popularity in breast augmentation and breast reconstruction. (1,2) This technique involves
harvesting fat using liposuction from donor sites, processing the extracted fat and reinjecting it back into the breast for the desired volume and shape. (3,4) Fat grafting has
gained popularity due to its resulting natural appearance and feel. This technique can also
be used in conjunction with implant reconstruction to achieve a more natural contour and
symmetry. (4,5) However, the main issue is an unreliable rate of fat retention, which,
based on the literature, is only an average of 60% of the volume of fat injected. (6,7)
Furthermore, there are very few clinical studies studying the long-term clinical
survivability of the grafted fat. Therefore, care must be taken in setting patient
expectations, and sometimes multiple sessions are required to achieve the desired results.
(8,9)
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Using a meta-analysis (chapter 2) to contrast fat grafting to implant based augmentation
suggested an improved patient satisfaction with implant over fat grafting. This is
speculated to be a result of variations in techniques leading to a lack of standardization
and therefore less predictable cosmetic outcomes.
Although the use of fat for augmentation has been around since 1893, the
relatively recent reemergence of its popularity has led to a multitude of harvesting and
processing techniques, with varying levels of success. (6) The overall gentle handling of
adipocytes with minimal disruption has been the general consensus. However, newer
technologies, such as power assisted liposuction have proven to be equally effective. (1)
Fat can be collected from any area of excess adiposity. (6) Once collected, several
products and processing solutions have been developed in recent years, including the
Revolve advanced adipose system (AbbVie/Allergan, USA), which is currently used at
our institution. (10)
Revolve is a device that has an inner filter basket where lipoaspirate is deposited
and an outer canister that collects the filtered fat after it has been separated from the
tumescent fluid, and the adipose tissue is irrigated using a Lactated Ringer’s solution.
(22,23) In animal studies, when compared to decantation, it has been demonstrated that it
has less blood debris and free oil as well as a higher percentage of adipose tissue and
retention and lower fat necrosis and need for revision. (22) (Figure 1)
Decantation is one of the most frequently used methods for fat processing and is
advantageous due to the simplicity and reproducibility of the technique relative to other
fat processing methods that exist. (19,20) Decantation for fat processing involves the use
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of gravity to separate the fat. (21) Retention rates of decantation range from 20% to 90%.
(18)

Figure 1. Revolve device connected as an intermediary to the liposuction cannula
and lipoaspirate collection container.

Over the past decade, simple decantation of fat by gravity (figure 2) or
centrifugation were the most common processing methods. (10,11) However, due to
damage to fat during processing and lower retention rates in the literature, centrifugation
has largely been abandoned as a processing method. (6,11) However, there is no standard
method of donor fat harvest or processing, and there is a lack of well-defined prospective
clinical studies comparing popular, more modern techniques in the current literature,
particularly in the long term. Additionally, the amount of fat injected and patient factors
such as previous radiation can affect the amount of fat retention.
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Figure 2. Lipoaspirate following decantation. Top layer of oils, middle layer of
adipose cells, bottom layer is a serosanguinous mixture of blood and tumescence.

In order to assess the rate of fat retention in the breast, volumetric imaging tools
have been validated in the literature. (12) One of the most popular techniques is 3D body
surface scans. (3,4,5,13) These can be taken easily, quickly, and cost-effectively for
volume assessment at various time points pre and postoperatively. (12) Comparatively,
MRI imaging has a much higher upfront, operating and interpretation cost, it’s more
time-consuming, and therefore not practical for frequent follow-up. Furthermore, as 3D
imaging becomes more accessible, cost-effective, and portable, its use could become
more common in clinical practice for preoperative planning and objective assessment of
outcomes. (14) A validation study done by Killaars et al. have shown that although MRI
is the current gold standard for volumetric analysis, 3D imaging systems, particularly the
VECTRA, were less accurate per independent measurement, however, with subsequent
measures, 3D imaging systems were comparable to MRI with excellent reliability.
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Currently, there is a lack of prospective clinical studies directly comparing the
rate of fat graft retention between processing techniques. The purpose of this clinical trial
is to evaluate two popular methods of fat processing; decantation and the Revolve
system. The primary outcome will assess long term fat survival and incorporation using
volumetric analysis and ultrasonographic imaging. The secondary outcomes include
comparisons of PROMs using BreastQ, operative time, surgical complications and
outcomes.
This trial is currently under review with Western Ontario’s research ethics board
(REB #11811) and is publicly available on www.clinicaltrials.gov (NCT05318716).

3.2
3.2.1

Methods
Patient eligibility

All patients presenting for fat grafting to four of our local breast surgeons will be
eligible to join this study. The treating surgeon will approach their patients undergoing
fat grafting for breast augmentation or reconstruction. Patients will need to consent for
3D imaging instead of standard 2D photography, pre-operatively and post-operatively, at
the standard follow-up imaging timepoints for this procedure to be eligible for
participation in this study. At any point in the study, patients will be permitted to
withdraw from participation in the study.
Inclusion criteria will include any patient above the age of 18 undergoing fat
grafting from any donor site to the breast for cosmetic or reconstructive purposes. The
exclusion criteria will include patients who are unable to consent to the study or are
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undergoing a repeat fat grafting procedure after a previous unsatisfactory result. Patients
who have undergone autologous breast reconstruction, including regional and free flaps
will be excluded. Patients who undergo multiple breast surgeries in the same sitting will
also be excluded (i.e., augmentation and mastopexy).

3.2.2

Recruitment
With our proposed prospective randomized controlled trial, we aim to recruit

patients already scheduled to undergo fat grafting to the breast for reconstruction or
cosmetic augmentation. A power analysis based on published image-based prospective
trials showed a minimum number of 22 patients. We will initially aim to recruit 100
patients into each of the cosmetic and reconstructive group, with a total of 200.
Each arm of patients will be divided further into high and low volume fat grafting,
this will leave us with enough power within each subgroup, which is above the current
standard in the literature for studies with statistical significance(15) (16). Based on the
clinical practice of the multiple breast surgeons who perform fat grafting at both our
centers, this would take 12-14 months to recruit enough patients.

3.2.2.1

Reconstruction (sub-group 1)

This group of patients would be undergoing fat grafting to correct contour
irregularities following implant-based reconstruction. Fat grafting would typically occur
for breast contouring 3-6 months following their initial implant-based reconstruction
procedure. On the day of their fat grafting appointment, the primary surgeon will provide
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them with the verbal information and answer their questions, as well as a letter of
information (LOI) (appendix 3). Pre-operative 3D imaging with volumetric analysis of
the patient’s breast will be done. This group will be analyzed based on injected volume
(<200 cc or <50% of pre-op breast volume and >200 cc or >50% of pre-op breast
volume) as well as subgroup analysis based on adjuvant chemo or radiation therapy to
minimize heterogeneity.

3.2.2.2

Cosmetic (sub-group 2)

This group of patients will be undergoing a primary or secondary augmentation
for cosmesis. They will be included if this is a primary augmentation using fat grafting or
a secondary augmentation (previous implant-based augmentation, now undergoing fat
grafting for further augmentation) with no history of fat grafting to the breasts. Patients
will undergo volumetric breast analysis similar to the above group.

3.2.3

Volume based analysis
Each of the above groups will be stratified based on baseline pre-treatment breast

volume, as well as injected volume. Each group will be divided into low volume, which
will be less than 200cc of injected fat or 50% of breast volume (whichever is lower)
needing replacement or augmentation. The high-volume group will include volumes
greater than 200cc or 50% of breast volume (whichever is higher) needing replacement or
augmentation.
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3.2.4

Imaging
A Vectra H2 (Canfield medical, NJ) will capture a 3D image in place of our

traditional 2D imaging, for both pre-operative and post-operative photos. A volumetric
analysis will be performed using the proprietary software. With a pre-operative baseline
volume, we will be able to track fat survival between the two-methods post-operatively
during follow up visits. We will include a bedside ultrasound image of the breast tissue at
3 months, to assess fat incorporation and the amount of oil and oil cysts. The
ultrasonographic image will be independently evaluated by a blinded assessor.

3.2.5

Randomization and Blinding
If a patient is included in the study, they will be randomized into either the

Decantation or Revolve group. A validated method of randomization will be used. When
the patients check in at the reception desk, they will be assigned a ticket with a 0 or 1
sequentially. This will be collected by the surgeon, and they will be able to set up for
either decantation or revolve. Group 0 patients will receive Decantation, and group 1 will
receive Revolve. The surgeon will make no mention of processing techniques in the
operative note. The surgeon will keep a log of their patients and processing technique
used on a secure shared file (file-safe, LHSC). The patient will be consented in the
regular manner as there are no additional risks with one method over the other.
Photography (VECTRA H2 imaging system) will be done by a separate research
assistant/coordinator that will be recruited for the project. The person will be responsible
for imaging patients, as well as conducting the volumetric analysis following training by
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the software manufacturer. This person will be blinded to which fat processing technique
was used. Photos will be kept on a secure network drive accessed in the research office,
as is standard practice for patient photographs in the department. Demographic data will
be collected, including patient age, weight, smoking status, radiation status (if
applicable), and reason for fat transfer to the breast. In addition, standard intraoperative
data will be taken, including length of procedure, volume of tumescent fluid injected,
volume of lipoaspirate, and volume of fat injected into each breast. 3D imaging will be
used to analyze the change in volume.
During subsequent follow ups, the patient will be assessed in the regular manner
with 3D volumetric imaging, in place of the standard 2D photography.
The surgeon, assistants and nurses will not be able to be blinded as they are
responsible for using the device in the operating room. All assessors will be blinded.

3.2.6

Standardized fat collection
The donor areas previously agreed on by the patient and surgeon for fat

harvesting will be injected with a pre-standardized formulae (Klein formulae for
tumescent fluid – 500mg Lidocaine, 1mg Epinephrine and 12.5 mEq sodium bicarbonate
per one liter of 0.9% normal saline) and volume of tumescent fluid. Fat will be extracted
using a standardized harvesting method between surgeons. Once the fat is collected. It
will then be processed in one of two ways depending on the patient’s group, using a
Revolve system or via decantation. Fat will then be injected into the breast using a 10 or
20cc syringe in the standard retrograde manner to achieve the desired size and shape. A
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standard gauze-based dressing will be applied post-operatively for 24 hours with no
compression. The patient will be allowed to shower and remove the dressing on postoperative day one and followed up in clinic two weeks following the procedure.
Post-operative follow up will be at two weeks (3D image), six weeks (3D image
and BreastQ), three months (3D image and Ultrasound), six months (3D image and
BreastQ), one year (3D image) and two years (3D image and BreastQ).

3.2.7

Statistical Analysis
Statistical analysis will be done by a contracted statistician for this study. The

level of significance for all statistical tests will be set at p < 0.05, with multiple
comparisons adjusted using Bonferroni coefficient. All analyses will be performed
according to the intention-to-treat principle. As appropriate, differences in dichotomous
outcomes will be assessed using the chi-square test or Fisher exact test. Differences in
continuous outcomes will be assessed using the independent-samples t-test or the Mann–
Whitney U test, as appropriate. Dichotomous outcomes will be reported as relative risks
(RRs) with corresponding 2-sided 95% confidence intervals (CIs). Continuous outcomes
will be reported as means with standard deviations (SDs) or as medians with interquartile
ranges (IQRs), depending on the data distribution. All statistical analysis will be done
using SPSS (IBM corporation, Armonk, NY).
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3.3

Conclusion

This RCT aims to explore the differences in the outcomes for patients who
undergo fat grafting using either Revolve or Decantation for fat processing. In this trial,
patients will be followed for up to 2 years post-operatively, which will provide an ample
amount of time for the fat to be incorporated, as well as assess the longevity of the
injected fat volume.
Fat grafting for breast augmentation is becoming increasingly more popular, and it now
poses the question of what processing method will achieve the most optimal results for
patients? (17) The goal of processing the fat is to remove contaminants, infiltration
solution, blood, cell fragments, and free oil to optimize the amount of active fat
constituents being transferred. (17,18) When the breast tissue is imaged at 3 months, the
echogenicity of the image will highlight how well the fat has incorporated, which could
ultimately predict better long-term results and volume stability.
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4

Discussion

4.1 Introduction
Breast Augmentation remains the most popular cosmetic procedure performed by
plastic surgeons around the world with current trends showing that this popularity is ever
growing. Patients have access to an extensive amount of information using the internet,
this, along with popular patient forums of social media, have caused a shift toward a ‘noimplant’ augmentation. Since 2009, there has been a steady upwards trend of autologous,
non-implant-based augmentation proving to be a viable and more so, desirable
alternative, this creates massive potential for surgical innovation and creativity.
More so, fat grafting has proven to be more than an adjunct procedure. Given the right
circumstances, patients can achieve their desired augmentation result, with larger fat
volumes in a single session. Fat grafting has also proven itself with no long-term adverse
events, and high levels of patient satisfaction.

4.2

Patient selection

As we outlined earlier, choosing the right patient for fat grafting is critical. These
days, patients are highly informed regarding their possible choices for primary breast
augmentation. A large portion of these patients are turning away from the use of
prosthetics. Opting for an autologous, and there for a more ‘natural’ augmentation.
Patients who are well informed regarding the post-operative course and possible pitfalls
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following fat grafting are excellent candidates if they are physically able to undergo fat
grafting.
Patients undergoing fat grafting must meet certain criteria, physically. There must
be enough excess fat to be harvested, taking into consideration the possibility of multiple
sessions. The breast itself, must have minimal ptosis with good quality skin. The breast
itself must have the ability to stretch to accommodate the required amount of grafted fat.

4.3

Operative Considerations

Preparation for surgery requires several considerations. Particularly regarding fat
harvesting. Popular harvest sites include the abdomen, thighs, and flanks. These areas
typically provide sufficient, high-quality fat for grafting. Equal attention should be paid
to contouring these areas during the harvest, to avoid post-operative asymmetry, seroma,
and hematoma formation. However, excess liposuction is discouraged, as to avoid excess
skin laxity. The current literature is inconclusive regarding the optimal sites to harvest
fat, however, there is weak data to suggest peri-umbilical fat to be slightly inferior.
Pre-operative photos of both the harvest and donor areas must be well
documented. As outlined in Chapter 3, the use of 3D imaging with volumetric analysis is
recommended. This would provide a quantifiable method of analysis and tracking postoperatively.
There have been a multitude of techniques and devices described for fat
harvesting. Manual syringe aspiration, power assisted, water assisted, and radiofrequency
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or ultrasound assisted liposuction, each with their own benefits. Power assisted
liposuction is much more efficient in harvesting larger volumes with no evidence to
suggest a superior harvesting method.
At present the options for processing the lipo-aspirate, include centrifugation,
decantation, and industry-devices, such as Revolve. Each with their own set of benefits,
and associated cost. At present, there is a community preference towards decantation and
industry-devices in place of centrifugation. The proposed RCT in chapter 3 should shed
more light on this important aspect of fat grafting. However, in-vitro studies have shown
a slight increase of viability of adipocytes processed with industry-devices, this has not
been reproduced clinically, to date.
Lastly, planning operative time and cost. An implant-based augmentation will
require 60-90 minutes of operating time, as well as the cost of the prosthetics. Fat
grafting is a longer process. Certain considerations include time for tumescence, time for
fat harvesting and fat processing. Patient positioning will also need to be considered,
depending on harvest sites. More so, many community centres do not have access to
liposuction devices or a limitation due to the cost of disposables. Therefore, manual
aspiration will take significantly longer and may not yield enough fat for larger augments.
Intra-operatively, there are considerably more surgical steps and two or more
surgical sites. Secondly, fat grafting requires a visual analysis and approach towards
breast volume and contouring by the surgeon. This requires the surgeon to add a
significant volume of fat to structurally enlarge the breast, while maintaining ideal breast
contour and shape.
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At present, implant-based augmentation still accounts for a large majority of
breast augmentation. Certain barriers are preventing the widespread adoption of fat
grafting augmentation. Primarily, the inability to ‘guarantee’ a reliable breast size postoperatively due to unpredictable fat necrosis. As well as a surgeon’s level of experience,
comfort and hesitation with augmenting and contouring a breast using fat. Humans are a
creature of habit; surgeons have gotten excellent results using implants for the past 60
years. These results are reproducible and as demonstrated in chapter 2, patients are
incredibly satisfied, more so than fat grafting.
The unpredictability of fat retention and analysis have been the toughest barrier.
More structured research into every step of fat harvesting, processing and injection must
be studied, as well as patient factors that may affect fat retention. Fat is autologous, and
inherently, will always have a certain amount of unpredictability compared to its
synthetic counterparts.
With implant-based augmentation, the data and evidence are quite clear regarding
the best surgical techniques and precautions to ensure the highest level of patient safety
and satisfaction. On the other hand, there are no standardized methods of fat harvesting,
processing, or injection. Moreover, there are no practical methods of assessing fat
survivability, particularly, in the longer term. Therefore, this method relies strongly on
patient selection and pre-operative counselling.
A comprehensive literature review regarding the current available evidence on fat
grafting showed inconsistencies regarding surgical technique and the pathophysiology of
fat survival. Although studies have demonstrated no significant differences with fat
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harvesting, the consensus has aligned with the gentle extraction of adipose tissue. The
processing of fat, however, has remained slightly more controversial. Previously,
centrifugation was considered standard practice to separate the layers of extracted fat for
injection, similar to other methods used for autologous injectables, such as platelet rich
plasma treatments. Over the past few years, centrifugation has been considered damaging
to fat cells and phased out of practice. At present, the predominant technique used is the
simple decantation of fat using gravity.
During decantation the adipose cells along with oils, tumescent fluid and blood
separate depending on their density. Injecting oils are particularly concerning as this can
create subcutaneous pockets of oil, which could be a source for infection. Newer industry
devices are processing and irrigating the fat to eliminate the aforementioned layers and
providing a ‘purer’ adipose product for injection. The literature is in disagreement and no
standardized clinical trials have been conducted to assess fat processing. Our proposed
RCT not only assesses the two methods of fat processing, but it also assesses surgical
outcomes, and PROMs as well. We also assess the fat incorporation within the breast
tissue itself at 3 months. This is significant, as we are assessing whether the volume is
from true fat retention or oil cysts. The long-term follow-up period of two years should
yield incredible qualitative and quantitative data regarding the fat grafting experience.
During the qualitative meta-analysis, we were able to see that the implant-based
augmentation group were ‘more satisfied’ than the fat grafting group post-operatively.
This is based on a significantly smaller cohort of fat grafting patients, where the data can
be easily skewed by outliers. The drastically different procedures and post-operative
recovery between the two methods of augmentation can also explain the difference.
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Where in most cases, implant-based augmentation continually improves from the
immediate post-operative period, that is not the case with fat grafting. As the fat settles
in, it can get hard and ‘cystic’ before it is ultimately incorporated to the surrounding
tissue. Fat grafting results are ultimately, in the long term, softer and more natural than
implants. Therefore, a longer follow up period might prove the inverse of what was found
in this meta-analysis.
However, the meta-analysis did show that in most recorded aspects on the
BreastQ questionnaire, there were no significant difference between the two methods of
augmentation from the patients’ perspective. However, they were overall, less satisfied.
This highlights the need for more high-quality data and studies regarding fat grafting.

4.4

Limitations

Overall, breast augmentation is an incredibly broad topic, particularly when
reviewing two popular surgical techniques. Although both fat grafting and implant-based
augmentation have a similar goal, they are incredibly different. The literature review
attempts to highlight the current knowledge and trends with both procedures, however,
there is still more to cover outside the scope of the review on implant selection, surgical
adjuncts, combination procedures and complications. Moreso, chapter one reviews the
current knowledge on adipose cell biology and the importance of adipose derived stem
cells, however, there are significant gaps in our knowledge and much that is unknown.
The meta-analysis, although attempting to answer a simple question, had
limitations with minimal pre-operative BreastQ data and the large discrepancy between
patient numbers. Although this did not affect the analysis, a larger fat grafting cohort
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might yield a different outcome, highlighting the need for more patient reported
outcomes and clinical research into fat grafting.
Although the randomized controlled trial is the first of its kind, there are still
obstacles due to the inherent nature of autologous tissue and clinical resources. The trial
addresses two popular methods of processing currently available at our centre, however,
we do not address centrifugation or ‘closed system’ fat grafting devices due to surgeon
preference and cost barriers. The trial also aims to assess fat grafting following one
session; however, a large percentage of patients would require multiple session to achieve
their desired result. This will inevitably result in earlier endpoints for certain patients and
their ineligibility to re-join the trial for the subsequent fat grafting session (due to the
exclusion criteria).

4.5

Conclusion

As we have established, the literature is saturated with data regarding various
methods of implant-based augmentation. Comparably, fat grafting data is relatively
sparse and inconsistent.
The popularity of fat grafting is expected to continue growing. It has proved itself
as a safe procedure, with good patient outcomes. However, more standardized methods
and clinical guidelines need to be established. The above trial could be a major step
towards more clinical evidence to the fat grafting body of knowledge. The implications of
this trial could influence both patients’ and surgeons’ decision, in the commonest
performed cosmetic surgery in the world
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Short Running Head:
PAP and LAP vs DIEP for breast reconstruction
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Abstract
INTRODUCTION:
Breast reconstruction with the deep inferior epigastric perforator (DIEP) flap is the
current gold-standard autologous option. The profunda artery perforator (PAP) and
lumbar artery perforator (LAP) flaps have been described as alternatives for patients who
are not candidates for a DIEP flap. The aim of this review was to compare the survival
and complication rates of PAP and LAP to DIEP flaps.
METHODS:
A literature search was conducted using PubMed, MEDLINE, EMBASE, BIOSIS, Web
of Science, and Cochrane databases. Papers were screened by title and abstract, and full
texts reviewed by three independent blinded reviewers. Quality was assessed using
MINORS criteria.
RESULTS:
Sixty-three studies were included, for a total of 745 PAP, 62 Stacked PAP, 187 LAP and
23748 DIEP flap breast reconstructions. The PAP (98.3%) had comparable success rate
to DIEP (98.4%), and the Stacked PAP (88.7%) and LAP (92.5%) success rate was
significantly lower (p<0.0001). The PAP and LAP groups had a significantly lower
incidence of fat necrosis, compared to the DIEP group (p<0.01 and p=0.02). However,
revision rate for the LAP group was significantly higher than the DIEP group (p<0.0001).
The PAP group also had a significantly higher rate of donor site wound dehiscence
(p<0.0001).
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CONCLUSION:
In conclusion, PAP, stacked PAP and DIEP flaps demonstrated similar overall survival.
LAP flap had a high survival rate, but lower than DIEP. This review highlights that PAP
flaps are a safe alternative for autologous breast reconstruction and may be a preferred
choice to LAP.
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Introduction
The deep inferior epigastric perforator (DIEP) flap is a well-established
autologous technique for breast reconstruction1–4. Originally designed as an alternative to
the transverse rectus abdominus myocutaneous (TRAM) flap, DIEP flaps preserve the
integrity of the rectus abdominis muscle, and results in decreased donor site morbidity1,5.
However, the lack of adequate donor site tissue or previous abdominal surgery can make
some patients unsuitable candidates for a DIEP flap.
Two new flaps, the profunda artery perforator (PAP) flap and the lumbar artery
perforator (LAP) flap have gained popularity as alternatives for autologous breast
reconstruction. The PAP flap harvests donor tissue from the posterior thigh6. Commonly,
patients have redundant tissue in this area, and benefits include a thigh contouring effect
and a easily hidden scar6,7. However, there is typically smaller tissue volume available,
and therefore may be ideal for women desiring a smaller reconstruction7. Alternatively, to
achieve a larger volume two PAP flaps may be used for unilateral breast reconstruction8,9.
Although technically challenging, stacked PAP flaps have been used with promising
post-surgical survival and aesthetic outcomes9.
The LAP flap harvests tissue from the lower back, ‘love handle’ region, another
common area of redundant tissue10. This flap is larger than PAP flap and comparable in
size to a typical DIEP flap11. There is minimal donor site morbidity and the scars are
easily hidden. The main challenge is positioning. The LAP flap must be harvested in the
prone or lateral decubitus position, and necessitates a position change to supine for
microvascular anastomosis and flap inset12. While this may lead to increased ischemia

97

98

time and technical challenges, initial studies have shown promising results for LAP-based
breast reconstruction11–13.
Presently, the DIEP flap is the gold standard for post-mastectomy autologous
tissue-based reconstruction. However, PAP and LAP flaps are promising alternatives.
They are especially useful for reconstruction in women with insufficient volume of
abdominal tissue, previous donor site surgery, previously failed reconstruction, poor
perforators, or patient preference for a non-abdominal flap. Survival outcomes and
complications associated with the PAP and LAP flaps have been reported, however, no
systematic review has been conducted comparing the outcomes or complications between
the DIEP flap and these two alternatives. The purpose of this review was to compare
breast reconstruction with PAP and LAP flaps to DIEP flaps, with the focus on flap
survival and complications.
Methods
Data Sources and Search Strategy
For this review, the Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) guideline was used (Figure 1). The PROSPERO database was
reviewed, and no similar review was found. The study was registered in the PROSPERO
database, number CRD42021238660. The search strategy was designed by two reviewers
(K.M. and V.C.). The search was conducted in two groups, the first for DIEP papers and
the second for the LAP and PAP papers. The search strategy included search terms
related to the flaps of interest, the region of interest, and terms related to the primary
outcomes and the secondary outcomes. Primary outcome was flap survival and secondary
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outcomes were common complications. Within each block items were combined with the
Boolean operator “OR”, and the three blocks were combined by the Boolean operator
“AND” to obtain the final search results. The search strategy is provided in Appendix 1.
To include the largest number of studies investigating breast reconstruction using
the autologous tissue flaps of interest, we systematically searched a total of six
bibliographic databases: BIOSIS®, PubMed®, Cochrane Library®, EMBASE®,
MEDLINE® and Web of Science®. The DIEP studies were searched on two dates,
February 17, 2021, and July 24, 2021. The search for PAP and LAP articles was
conducted on June 7, 2021.
In addition, we manually screened references from relevant review articles to
identify pertinent studies that escaped our search strategy.
Inclusion and Exclusion Criteria
Inclusion and exclusion criteria were determined a priori. Due to the anticipated
large number of DIEP studies available compared to PAP and LAP, we developed two
sets of inclusion and exclusion criteria. We included prospective studies, retrospective
studies and randomized controlled trials written in English or French, published in peer
reviewed journals. For the DIEP papers we included studies published in 2012 or later
with an N >/=10 flaps. For the LAP and PAP papers we included studies published in
2012 or later with N>1 flaps. Of these studies, we included those that reported outcome
measures involving flap survival. Case reports, reviews, animal studies, conference
proceedings, abstracts and editorials were excluded. We also excluded any study that
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non-randomly selected a specific subset of breast reconstruction patients from a larger
dataset (Table 1 and 2).

Study Selection
Studies extracted underwent two levels of screening by three independent
reviewers (K.F., K.M and V.C) using Rayyaan and Covidence platforms (Rayyaan
Systems Inc., Cambridge, MA, USA and Covidence systematic review software, Veritas
Health Innovation, Melbourne, Australia). For Level 1 screening, studies titles and
abstracts were reviewed. Selected articles underwent full-text review. Assessment of
quality was conducted for all non-randomized studies selected using the Methodological
Index for Non-Randomized studies (MINORS) score. Papers that failed to achieve a
score of 60% or higher were excluded. Reasons for exclusion were documented and
reported in the PRIMSA flowchart (Figure 1). All conflicts were resolved between
reviewers, and an independent arbitrator (K.A.) was available for any disputed conflicts.
Data Extraction
Data was extracted using the Google Sheet platform (Google, Mountain View,
CA, USA), and reviewed by two additional independent reviewers (E.L. and K.J) for
errors. Disagreements were discussed with both sets of reviewers to resolve conflicts.
Data extracted included study information, number of patients, demographic
characteristics, flap characteristics, and primary and secondary outcomes.
Statistical Analysis
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Statistical analysis was conducted using SPSS and GraphPad Prism 9 software
(IBM, Armonk, NY, USA and GraphPad Software, Inc., San Diego, CA). Descriptive
statistics were calculated for demographic data with weighted means, and standard
deviation. Chi-square with Yate’s continuity correction test was used to analyze primary
and secondary outcomes. Cohen’s kappa coefficient was calculated to assess for interrater reliability for article selection, with values 0.41-0.60, 0.61-0.80 and 0.81-1.00
representing moderate agreement, substantial agreement, and perfect agreement
respectively14.
Results
Study Characteristics and Demographics
The search strategy identified 2430 articles, and an additional 6 were added from
other sources. After removal of duplicates, 1448 articles were screened using title and
abstract and 166 articles underwent full text review (Figure 1). In total, 61 full-text
articles were included for data extraction, representing a total of 24742 free-flaps for
breast reconstruction. Fourteen of the studies were PAP focused7,8,15–25, six were
LAP12,13,26–29 focused and forty-one DIEP focused2,12,15,30–66. Of the PAP focused papers,
three included outcomes from stacked PAP flaps for unilateral breast reconstruction8,16,20.
Cohen’s Kappa coefficient was 0.87 between K.M. and V.C. for the DIEP studies, and
0.89 between K.F. and V.C. for the PAP and LAP study selection. Table 2 summarizes
the characteristics of articles included in this review. Data was extracted from a total of
745 PAP flap, 62 Stacked PAP flap, 177 LAP flap and 23748 DIEP flap breast
reconstructions.
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Patient demographic data for age, BMI and flap weight was extracted for each
flap group (Table 4). Weighted mean and standard deviation were calculated using the
number of flaps in each study reporting demographics as the frequency variable. Average
age 46.7 +/- 2.9 and 48.5 +/- 3.2 for PAP and LAP respectively compared to 50.4 +/- 2.0
for DIEP (Table 4). The PAP and LAP groups also had lower average BMI, 24.2 +/- 2.2
and 23.9 +/- 1.4 respectively, compared to the DIEP group, 27.1 +/- 2.4 (Table 4). For
flap weight, the DIEP flap average was the highest, at 628.7 +/- 97.4g, the LAP average
was 533.2 +/- 56.8g and single PAP flaps were the lowest average at 374.4 +/- 55.6g. Of
the three stacked PAP papers one reported the average combined flap weight as 420+/164.8g8.
Primary Outcomes
Primary outcomes were analyzed in two ways. First, we compared flap survival
and loss, between the PAP, stacked PAP, LAP and DIEP groups (Table 5). Flap survival
was defined as flaps reported as full and partial survival. All flaps had high survival rates,
with 98.4% for DIEP, 98.3% for PAP, 88.7% for stacked PAP and 92.5% for LAP. Table
5 shows there is no significant difference between flap survival for PAP (p=0.8)
compared to DIEP. However, the stacked PAP and LAP groups had significantly lower
survival rate compared to DIEP (p<0.001).
Second, we analyzed full flap loss and partial flap loss rates. There was no
significant difference in complete flap loss for PAP (p=0.8) compared to DIEP (Table 6).
There was a significantly higher rate of complete flap loss for the stacked PAP and LAP
flap (p<0.0001). Interestingly, the PAP group had a significantly lower partial loss rate,
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0.3% compared to the DIEP group, 1.1% (p=0.05). The LAP partial flap loss rate was
0.6% (p=0.8).
Of the LAP flaps reported, 171 (96.6%) used artery and vein interposition grafts
(Table 7). Table 7 shows the operative positioning and vein graft usage, as well as
corresponding ischemia time and operative time.
Secondary Outcomes
Secondary outcomes included fat necrosis, revision surgery and donor site wound
dehiscence. Revision surgery was defined as any report of re-operation for complications,
most commonly for microvascular compromise. Other causes included hematoma, fat
necrosis, and wound dehiscence. Revision for aesthetics was not consistently reported,
and therefore was excluded from analysis.
Table 8 shows reconstruction with a single PAP flap resulted in significantly
lower rates of fat necrosis, 2.6% compared to DIEP, 7.7% (p<0.01). There were no
reported cases of fat necrosis in the LAP flap group (p=0.2).
The PAP group had a comparable rate of revision surgery, 3.3%, compared to
5.2% to the DIEP group (p=0.2). There was a significantly higher rate of revision of
16.1% in the LAP group (p<0.0001). Revision of stacked PAP flaps was not reported.
Incidence of donor site wound dehiscence was 9.1% of cases in the PAP group,
which was significantly higher than 3.4% in the DIEP group (p<0.001). There was no
significant difference in donor wound dehiscence rate for LAP flaps compared to DIEP
(Table 8).
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Two PAP papers reported the rate of revision for solely aesthetic reasons.
Hupkens et al. 2016, reported a 30% rate of secondary fat grafting, while Tielemans et al.
2021 reported a rate of 67.8%. Wade et al. reported a liposuction/lipofilling rate of 11.6%
in unilateral and 10.3% in bilateral breast reconstruction with DIEP flaps.
Discussion
Our study demonstrates that the PAP flap is comparable to the gold standard
DIEP flap for reconstructive surgery after mastectomy. The LAP flap had significantly
higher rates of failure compared to the DIEP flaps. This is the first systematic review
directly comparing the outcomes of breast reconstruction with PAP and LAP flaps to
DIEP.
As reported previously, our review found patients chosen for PAP and LAP flap
reconstruction were generally younger and had a lower BMI than DIEP patients11,67. The
PAP and LAP flap reconstruction offer benefits in situations where patients are not ideal
candidates for a DIEP flap, due to previous abdominal surgery or lack of redundant
abdominal tissue, or who do not want an abdominal scar7,9. One patient group who may
benefit from a PAP or LAP reconstruction is gene mutation carriers high-risk for breast
cancer, such as BRCA-positive patients, desiring prophylactic mastectomy and
autologous reconstruction. These patients are commonly younger and slimmer than
typical breast cancer patients, and therefore may not be ideal DIEP candidates11,12.
Therefore, depending on the breast size desired, a bilateral PAP or LAP-based
reconstruction may be an alternative.
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Patients undergoing mastectomy for unilateral breast cancer may be another
candidate group. Currently, the role of concurrent contralateral prophylactic mastectomy
for non-gene mutation carrier patients is controversial68. When undergoing DIEP
reconstruction all abdominal tissue must be removed50. Therefore, if patients develop
breast cancer on the contralateral side, or a recurrence, they will no longer have tissue for
a DIEP reconstruction. This could lead patients to consider undergoing prophylactic
mastectomy and bilateral DIEP reconstruction unnecessarily. Having viable alternatives
may give patients more options and peace of mind for possible future reconstructive
options.
We reported an overall flap failure rate of 1.7% in the PAP group and 1.6% in the
DIEP group. Two previous reviews reported a failure rate of 2.67% for DIEP flaps, and
1% for PAP flaps69,70. Additionally, we found that PAP flap reconstructions had lower
rates of partial failure than DIEP flaps, a complication that can result in the need for
revision surgery, and a poorer aesthetic outcome69. The major downside of the PAP flap
is the size. This can be overcome by using two PAP flaps can be combined to reconstruct
a single breast, for a ‘stacked PAP’ reconstruction. Our review found higher rates of
failure in the stacked PAP group, however one paper accounted for six out of seven total
failures.
Comparatively, the LAP flap had a failure rate of 7.5%, which was significantly
higher than the DIEP flap. The main advantage of the LAP flap is its size, favorable
donor site quality of tissue and aesthetic outcome. We reported a mean flap weight of
533.2g, consistent with analysis done in previous literature that it is comparable to the
size of a DIEP flap39. Slim patients, or those who have undergone abdominoplasty, often
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have redundant tissue in the flank area, and the LAP flap has the simultaneous advantage
of giving a buttock lift effect.
One factor possibly contributing to the higher rate of failure in LAP flaps include
the use of interposition grafting. The LAP flap typically has a shorter pedicle and smaller
vessel diameter, with three studies reporting averages of 4.5cm, 5.25cm and 6cm mean
pedicle length12,26,28. Opsomer et al. describe that although a pedicle length of up to 7cm
is possible, their group no longer pursues this length to avoid a deep dissection around the
transverse process that can lead to nerve root damage and neurapraxia of the leg11. We
found the majority of LAP flap reconstructions used artery/vein interposition grafts,
which requires two anastomoses and can increase the risk of vessel thrombosis12. Indeed,
Peters et al. noted that of the six flaps they had to take-back to the operating room, in five
flaps the vein had thrombosed at the site of the vein graft and pedicle anastomosis26.
The LAP flap is a logistically challenging flap, that requires intraoperative
position change. The majority of flaps were harvested in prone positioning and
anastomosed in supine, necessitating donor site closure and patient repositioning in
between12,13. Additionally, the surgeon also has to anastomose the graft to the pedicle.
Both these factors can increase ischemia time. Increased ischemia time can increase the
risk of ischemia reperfusion injury and has been correlated with increased failure rates in
DIEP flaps53,71. One LAP study reported mean ischemia time of 65 minutes without a
graft, compared to 131 minutes when a graft was used26. This prolonged ischemia time
has led some surgeons to not attempt simultaneous bilateral LAP flap reconstruction. One
study included bilateral LAP flap reconstruction with 15 patients, and experienced two
flap losses13. Although this is promising that the ischemia time was not prohibitive, the
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procedure was completed by two experienced microsurgeons preforming simultaneous
harvest13.
In terms of complications, PAP and LAP reconstruction demonstrated low rates of
fat necrosis, however the LAP group had increased revision rates, and PAP had increased
donor site wound dehiscence compared to DIEP. Factors affecting ischemia, such as flap
size and number of perforators predict fat necrosis, and patient factors that affect
perfusion such as smoking status, previous abdominal surgery and radiation history are
believed to contribute to its development72. The PAP flap is a smaller flap than DIEP, and
therefore the lower rate of fat necrosis is expected. There are also confounding variables
such as smoking and radiation that was not consistently reported and could explain this
result. In both PAP and LAP groups, revision surgery was significantly higher than DIEP.
For the PAP group this may be due to the increased rate of lipofilling done, which one
study reported was done in up to 67.8% of PAP flap reconstructions24. Donor site wound
dehiscence was most prevalent in the PAP group at 9.1% compared to 3.4% for DIEP and
2.9% for the LAP groups. This is likely due to strain placed on the donor site wound from
sitting. Improved post-operative wound care and patient education for ideal positioning
may be needed to achieve comparable surgical outcomes in this area.
Limitations to this study include the discrepancy in sample size between DIEP
flap and PAP and LAP flap reconstructions extracted from the literature. Specifically, for
the LAP and stacked PAP group, the sample size is such that the outcomes from one
study can influence the overall result reported in this review. Furthermore, the majority of
studies did not report their definition of partial flap loss, and of those that did report, the
definition ranged from greater than twenty to fifty percent flap necrosis. Similarly the
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data for fat necrosis was based on inconsistent definitions, most commonly greater than
2cm palpable mass, however some reported as greater than 1cm, or with ultrasound
detection. Therefore, these results may be biased based on the authors definition.
Additionally, confounding factors for surgical outcomes such as smoking status and use
of adjuvant chemotherapy or radiation was not consistently reported. Patient satisfaction
and aesthetic outcome data was also lacking. Importantly, most data published from the
PAP and LAP flaps come from a relatively small group of surgeons who do a high
volume of these alternative flaps and therefore, there is likely a learning curve associated,
and the failure rates may be higher for surgeons with less experience in these flaps.

Conclusion
Although the DIEP flap remains the gold standard for autologous breast
reconstruction, our systematic review presents the PAP flap as the favorable alternative
over the LAP flap. The major advantage of the PAP flap is its high success rate
comparable with DIEP. The disadvantages remain the flap size, as well as increased
donor site complication rates. The advantages of the LAP flap identified were the size
and donor site outcomes. However, the LAP flap has a significantly higher rate of failure
and therefore inferior as an alternative reconstructive option compared to the PAP flap.
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APPENDIX 2 – Search Strategy

A. Search terms
(((“Fat” AND (“transplant*”OR “graft*” OR “transfer” OR “autograft*” OR
"autologous transplant*" OR “sculpt*” OR “inject*”)) OR (“adipose” AND
(“transplant*”OR “graft*” OR “transfer” OR “autograft*” OR "autologous
transplant*" OR “sculpt*” OR “inject*”)) OR (“adipocyte” AND
(“transplant*”OR “graft*” OR “transfer” OR “autograft*” OR "autologous
transplant*" OR “sculpt*” OR “inject*”)) OR (“lipo” AND (“transplant*”OR
“graft*” OR “transfer” OR “autograft*” OR "autologous transplant*" OR
“sculpt*” OR “inject*”)) OR (“autologous” AND (“transplant*”OR “graft*” OR
“transfer” OR “autograft*” OR "autologous transplant*" OR “sculpt*” OR
“inject*”)) OR (“autologous” AND “Fat” AND (“transplant*”OR “graft*” OR
“transfer” OR “autograft*” OR "autologous transplant*" OR “sculpt*” OR
“inject*”)) OR (“homologous” AND (“transplant*”OR “graft*” OR “transfer”
OR “autograft*” OR "autologous transplant*" OR “sculpt*” OR “inject*”)) OR
(“homologous” AND “Fat” AND (“transplant*”OR “graft*” OR “transfer” OR
“autograft*” OR "autologous transplant*" OR “sculpt*” OR “inject*”)) OR
(“autogenous” AND (“transplant*”OR “graft*” OR “transfer” OR “autograft*”
OR "autologous transplant*" OR “sculpt*” OR “inject*”)) OR (“autogenous”
AND “Fat” AND (“transplant*”OR “graft*” OR “transfer” OR “autograft*” OR
"autologous transplant*" OR “sculpt*” OR “inject*”)) OR “Autograft*” OR “soft
tissue augmentation” OR “autotransplant*” OR "adipose tissue/transplantation"
OR (“adipose” AND “tissue” AND “transplant*”) OR “lipostructur*” OR
“lipoinfiltr*” OR “lipomodel*” OR “lipotransf*” OR “lipo-transf*” OR
“lipofill*” OR “lipo-fill*” OR “lipoinfil*” OR “lipo-infil*” OR “lipoaugmen*”
OR “lipo-augmen*” OR “fat-augmen*” OR “lipoplasty” OR "lipectomy" OR
“liposculpt*” OR “lipoinject*” OR “lipo-inject*” OR “fat fill*” OR
“microlipoinjection*” OR “lipoaspirate*” OR “lipotransplant*” OR
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“microlipofill*” OR “micro-lipofill*”) OR ((“breast” AND (“implant*” OR
“prosthes*” OR “endoprosthesis”)) OR (“mamma*” AND (“implant*” OR
“prosthes*” OR “endoprosthesis”)) OR (“silicon*” AND (“implant*” OR
“prosthes*” OR “endoprosthesis”)) OR (“saline” AND (“implant*” OR
“prosthes*” OR “endoprosthesis”)) OR (“gel” AND (“implant*” OR “prosthes*”
OR “endoprosthesis”)) OR (“alloplast*” AND (“implant*” OR “prosthes*” OR
“endoprosthesis”)) OR “smooth implant*” OR “textured implant*” OR
“Structured saline implant*” OR “Gummy bear implant*” OR “round implant*”
OR “teardrop implant*” OR “Silicone gel implant*” OR “Internal Breast
Prosthes*” OR “breast implant surgery”)) AND (“Breast augment*” OR
“augmentation” OR “mammaplast*” OR “mammoplast*” OR “breast
enlargement” OR “breast enhanc*” OR “Augmentation mammaplasty” OR
“augmentation mammoplasty” OR “cosmetic breast augment*” OR “aesthetic
breast augment*” OR “aesthetic breast enhanc*” OR “cosmetic breast enhanc*”)
AND (“BREAST-Q” OR “Breastq” OR “breast questionnaire*” OR “Breast-Q
questionnaire”)

120

121

B. PRISMA diagram for records screened, and final papers included in data
extraction and analysis.

Identification

PRISM A 2009 Flow Diagram

Records identified through
database searching
(n = 1398)

Additional records identified
through other sources
(n = 5)

Included

Eligibility

Screening

Records after duplicates removed
(n = 597)

Records screened
(n = 597)

Records excluded
(n =540)

Full-text articles assessed
for eligibility and quality
(n = 57)

Full-text articles excluded,
with reasons
(n = 35)

Studies included in
qualitative synthesis
(n = 22)

Non BREASTQ (n = 18)
Wrong population (n=4)
Wrong publication type
(n=6)
Duplicate Dataset (n = 3)
Full text not found (n =1)
Language (n= 3)

Studies included in
quantitative synthesis and
meta-analysis
(n = 14)
(Fat graft = 2 )
(Implant = 10)
(Implant & fat graft = 2)

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.
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C. MINORS score template
The revised and validated version of MINORS Methodological items for nonrandomized studies Score.
The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and
adequate). The global ideal score being 16 for non-comparative studies and 24 for
comparative studies.
Score
1. A clearly stated aim: the question addressed should be precise and relevant in the light of
available literature
2. Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the
criteria for inclusion) have been included in the study during the study period (no exclusion
or details about the reasons for exclusion)
3. Prospective collection of data: data were collected according to a protocol established
before the beginning of the study
4. Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria
used to evaluate the main outcome which should be in accordance with the question
addressed by the study. Also, the endpoints should be assessed on an intention-to-treat
basis.
5. Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and
double-blind evaluation of subjective endpoints. Otherwise, the reasons for not blinding
should be stated
6. Follow-up period appropriate to the aim of the study: the follow-up should be
sufficiently long to allow the assessment of the main endpoint and possible adverse events
7. Loss to follow up less than 5%: all patients should be included in the follow up.
Otherwise, the proportion lost to follow up should not exceed the proportion experiencing
the major endpoint
8. Prospective calculation of the study size: information of the size of detectable difference
of interest with a calculation of 95% confidence interval, according to the expected
incidence of the outcome event, and information about the level for statistical significance
and estimates of power when comparing the outcomes Additional criteria in the case of
comparative study
9. An adequate control group: having a gold standard diagnostic test or therapeutic
intervention recognized as the optimal intervention according to the available published
data
10. Contemporary groups: control and studied group should be managed during the same
time period (no historical comparison)
11. Baseline equivalence of groups: the groups should be similar regarding the criteria other
than the studied endpoints. Absence of confounding factors that could bias the
interpretation of the results
12. Adequate statistical analyses: whether the statistics were in accordance with the type of
study with calculation of confidence intervals or relative risk
Total
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APPENDIX 3 – Letter of Information

LETTER OF INFORMATION and CONSENT

The Fat Analysis Trial (FAT): The Impact of Lip-aspirate Processing on Fat
Resorption in Autologous Fat Grafting to the Breast: A Randomized Controlled
Trial
Principal investigator
Tanya Delyzer, MD, FRCSC
Co-investigators
Arjang Yazdani, MD, FRCSC
Khalifa AlGhanim, MD

Introduction
You are being invited to voluntarily participate in this study because you will be scheduled
to have fat grafting for breast augmentation and/or reconstruction. Before you decide to
participate, it is important for you to know why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it with
your family, friends, and/or your doctor as you wish. There may be words or statements
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that you do not understand. Ask your study doctor or study staff to explain anything that
is not clear or if you would like more information. Take time to decide whether or not you
wish to take part.
In this consent document, “you” always refers to the study participant. If you are a
substitute decision maker (SDM) (i.e. someone who makes the decision of participation
on behalf of a participant), please remember that “you” refers to the study patient. If an
SDM is needed for this study, you will be asked to review and sign this consent form on
behalf of the participant.
Before agreeing to participate in this study, it is important that you know about the study.
This document describes the purpose, procedures, benefits, discomforts, and risks
associated with this study, as well as your rights if you decide to participate in this study.
Why is this study being done?
Fat grafting is a commonly used technique that involves harvesting fat using liposuction,
processing the fat, and then injecting it into the breast for augmentation or reconstruction.
There is currently no standard method for fat processing. The downside of fat grafting is
the fact that fat can get reabsorbed into the body after surgery. This can often be
unpredictable and can lead to undesired cosmetic results.
The goal of this study is to compare two common fat processing methods to determine if
one is better than the other at reducing the amount of fat that is reabsorbed into the body
from the breasts after surgery.
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How many people will take part in the study?
200 patients will participate in this study at London Health Sciences Centre and St. Joseph’s
Hospital (100 patients will be scheduled for fat grafting for the purposes of breast reconstruction
and the other 100 will be scheduled for fat grafting purely for cosmetic breast augmentation).
What is involved in the study?
If you choose to take part in this study, you will be randomly selected to be part of
one of two groups:
1) Decantation Group – The use of gravity to separate the different layers of
the fat prior to injection.
2) Revolve Group – The use of a medical device, which will collect the fat
and suction off the fluid and oils, leaving the fat behind, to be injected.
For each group, the following will be done:
● Breast volume will be measured before and after surgery using a noninvasive 3D imaging technique.
● BreastQ questionnaire will be filled in before the procedure

At the post-surgery check-up:
● Breast volume will be measured using a non-invasive 3D imaging
technique.
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Three months after surgery:
● BreastQ will be completed again.
● A non-invasive ultrasound of the breast tissue will be done in clinic.
How long will I be in the study?
If you choose to take part in this study, you will have your regular follow up
appointments, up to two years following the procedure.
Are there benefits to taking part in the study?
If you agree to take part in this study, there may or may not be direct medical
benefit to you. We hope the information learned from this study will help guide
plastic surgeons in the future and will ultimately increase patient satisfaction in
the future.
What are the risks of the study?
There are risks associated with the procedure, however, there are no additional
risks if you take part in this study.
What about privacy and confidentiality?
All data that will be collected from this study will be considered confidential. We will
maintain your confidentiality by using a unique identifier number (a study ID) on all
documents instead of your name. A separate secure document will contain the linkage
between your name and study ID to minimize the possibility of a privacy breach. This list
will be kept in a secure place, separate from your study file. Your research records will
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be stored in a locked cabinet in Dr. Delyzer’s office and kept in electronic format in a
password protected file behind the hospital firewall. Any data that we collect for this
study will not include identifying information other than your study ID in order to protect
your confidentiality. If the results of the study are published, your name will not be used
and no information that discloses your identity will be released or published without your
explicit consent.
By signing the consent form, you hereby consent to participation in this study. By
consenting to this study, you agree to allow us to confidentially collect this data. If you
do not consent to this data collection, then you cannot participate in this study.
Representatives of Western University Health Sciences Research Ethics Board and the
Lawson Health Research Institute’s Quality Assurance and Education Program may
contact you or require access to your study-related records to monitor the conduct of the
research.
The study doctor will keep any personal health information about you in a secure and
confidential location for a minimum of 15 years as required by Lawson Health Research
Institute policy.
If, during the course of this study, new information becomes available that may relate to
your willingness to continue to participate, this information will be provided to you by
your study doctor.
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What are my rights as a research participant?
Your participation in this study is voluntary. You may refuse to participate, refuse to
answer any questions, or you may withdraw from the study at any time with no effect on
your future care. If you decide not to participate or if you withdraw from the study
before it is completed, the alternative procedures or courses of action will be explained to
you by your doctor.
We will tell you about new information that may affect your health, welfare, or
willingness to stay in this study. If the results of the study are published, your name will
not be used. If you would like to receive a copy of the overall results of this study, please
put your name and address on a blank piece of paper and give it to the Clinical Research
Associate.
What are the costs?
You will not be paid for taking part in this study.
In the case of research-related side effects or injury, medical care will be provided by
your study doctor or you will be referred for appropriate medical care. No funds have
been set aside to compensate you in the event of injury or illness related to the study
treatment or procedures. You do not waive any of your legal rights by signing the consent
form.
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Whom do I call if I have questions or problems?
If you have questions about this study, you can talk to your doctor. You can also talk to
the doctor who oversees the study at this institution

Dr. Tanya Delyzer

If you have any questions about your rights as a research participant or the conduct of this
study, you may contact the Patient Relations Office at LHSC at (_______ ext. ___)

24 hour contact number - LHSC at __________ [Plastic surgery resident on call]

If a medical emergency arises, proceed to your local Emergency Department.

A copy of this letter will be made for you to keep.
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CONSENT FORM
The Fat Analysis Trial (FAT): The Impact of Lip-aspirate Processing on Fat
Resorption in Autologous Fat Grafting to the Breast: A Randomized Controlled
Trial
I have read the accompanying letter of information and have had the nature of the study explained
to me and I agree to participate. All questions have been answered to my satisfaction. Upon
signing this form, I will receive a copy.

________________________________

__________________

Signature of Participant

Date

________________________________
Name of Participant

________________________________

___________________

Signature of Person Conducting

Date

The Informed Consent Discussion
________________________________
Name of Person Conducting
The Informed Consent Discussion
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□ The person signing below acted as a translator for the participant during the consent process
and attests that the study as set out in this form was accurately translated and has had any
questions answered.

________________________________

___________________

Signature of Interpreter Aiding

Date

The Informed Consent Discussion

________________________________

___________________

Name of Interpreter Aiding

Language

The Informed Consent Discussion
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APPENDIX 4 – BREASTQ
BREASTQ

Scale

Scale
Component

Instruction
Response
option
Response
option
Response
option
Response
option
APPEARANCERELATED
PSYCHOSOCIAL
DISTRESS

Item
Item
Item
Item
Item
Item
Item
Item

Instruction

EXPECTATIONS

Response
option
Response
option
Response
option
Response
option

Circle only one answer for each statement. These phrases may be used by
people to describe themselves. Regarding your appearance - To what extent do
you disagree or agree with each statement:
Never agree
Somewhat disagree
Somewhat agree
Definitely agree
1. I feel sad about how I look.
2. I feel nervous about how I look.
3. I feel frustrated about how I look.
4. I feel anxious when people look at me.
5. I fear that my appearance is not normal.
6. I am afraid of being ugly.
7. I tend to avoid staying among people.
8. I have little interest in doing things.

Circle only one answer for each statement. These phrases people may use to
describe how their lives will change after a cosmetic surgery. Regarding your
appearance - To what extent do you disagree or agree with each statement:
Never agree
Somewhat disagree
Somewhat agree
Definitely agree
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Item
Item
Item
Item
Item
Item
Item
Item

Instruction
Response
option
Response
option
Response
option
Response
option
BODY IMAGE

Item
Item
Item
Item
Item
Item
Item

SOCIAL
FUNCTION

Instruction
Response
option

1. I will look great.
2. People will tell me how great I look.
3. People closest to me will be proud of my appearance.
4. I got to change.
5. Good things will happen to me.
6. I will feel as if my condition is right.
7. My close relationships will improve.
8. New people will try getting to know me.

Circle only one answer for each statement. Regarding your body - and
considering the last week - To what extent you disagree or agree with each
statement:
Never agree
Somewhat disagree
Somewhat agree
Definitely agree
1. I feel positive about my body.
2. My body is not perfect, but I love it like this.
3. I am happy with my body.
4. I am proud of my body.
5. I see I have an attractive body.
6. I feel good about my body when I get naked.
7. I have the body I wish.

Circle only one answer for each statement. Regarding your body - and
considering the last week - To what extent you disagree or agree with each
statement:
Never agree
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Response
option
Response
option
Response
option
Item
Item
Item
Item
Item
Item
Item
Item
Item
Item

PSYCHOLOGICAL
FUNCTION

Instruction
Response
option
Response
option
Response
option
Response
option

Somewhat disagree
Somewhat agree
Definitely agree
1. I feel comfortable in social gatherings with people I know.
2. People listen to what I have to say.
3. I feel accepted by people.
4. I feel integrated in social situations.
5. I leave a good first impression.
6. Take part in life instead of being humble.
7. It is easy for me to make new friends.
8. I feel confident when I am at events with gatherings (such as: meetings).
9. I feel comfortable around people I don't know well.
10. I feel confident when entering a room full of people, I don't know.

Circle only one answer for each statement. Regarding your body - and
considering the last week - To what extent you disagree or agree with each
statement:
Never agree
Somewhat disagree
Somewhat agree
Definitely agree

Item

1. I trust myself.

Item

2. I am proud of myself.

Item

3. I feel happy.

Item

4. I love myself.

Item

5. I am a deeply emotional person.

Item

6. I feel being able to control my life.
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Item

7. I feel confident.

Item

8. I feel self-acceptance.

Item

9. I am at peace with myself.

Item

10. I feel proud of myself.

Instruction
Response
option
Response
option
Response
option
Response
option
PHYSICAL
FUNCTION

PHYSICAL
SYMPTOMS

Circle only one answer for each question. Regarding your bod - and considering
the past week - how often have you had a problem with:
Always
frequently
Sometimes
Never

Item

1. Getting out of bed?

Item

2. Bending from side to side?

Item

3. Walking or moving?

Item

4. Bending over (for example: to tie your shoes)?

Item

5. Do moderate-Intensity exercises (for example: jogging)?

Item

6. Going up or down stairs?

Item

7. Standing for a long period of time?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Regarding your body - and considering
the last week - How many times this has happened to you:
Always
frequently
Sometimes
Never

Item

1. Feeling tired throughout the day?

Item

2. Back pain?
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SEXUAL
FUNCTION

SATISFACTION
WITH
ABDOMEN

Item

3. Joint pain?

Item

4. Leg pain or discomfort?

Item

5. Feeling unbalanced?

Item

6. Feeling weak?

Item

7. Shortness of breath with light exercise?

Item

8. Swollen feet?

Item

9. rash or skin infection?

Item

10. Excessive sweating?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each statement. Regarding your own body - To what
extent do you disagree or agree with each statement:
Never agree
Somewhat disagree
Somewhat agree
Definitely agree

Item

1. Sex is satisfactory to me.

Item

2. I am comfortable taking off my clothes in front of my life partner.

Item

3. I am satisfied with my sexuality.

Item

4. I feel comfortable if the lights are on during sex.

Item

5. I feel sexy attractive if I am without clothes

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Considering your belly (any abdomen
or stomach area) - over the last week - How satisfied or dissatisfied are you with
the following:
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied
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SATISFACTION
WITH BACK

SATISFACTION
WITH BODY

Item

1. How well your clothes fit your belly?

Item

2. The size of your belly?

Item

3. The shape of your belly from the side (the side view)?

Item

4. The shape of your belly?

Item

5. What does your belly look like in a swimsuit?

Item

6. What do your stomach muscles look like?

Item

7. What shape is your belly when you are naked?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Considering your back - over the last
week - How satisfied or dissatisfied are you with the following::
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. How smooth is your back?

Item

2. What does your back look like from different angles?

Item

3. The shape of your back muscles?

Item

4. The shape of your back when you are naked?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Considering your whole body - over
the last week - How satisfied or dissatisfied are you with the following::
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. What does your body look like while you are dressed?

Item

2. How well your clothes fit your body?
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SATISFACTION
WITH
BUTTOCKS

Item

3. The size (any weight) of your body?

Item

4. Your body shape?

Item

5. What is your body like in pictures?

Item

6. Your body shape from behind?

Item

7. What is your body shape from the side (the side view)?

Item

8. The shape of your body in summer clothes (such as shorts and t-shirts)?

Item

9. What does your body look like in a swimming suit?

Item

10. What is your body shape on the mirror without clothes?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Considering your buttocks in mind over the last week - How satisfied or dissatisfied are you with the following:
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. The size of your buttocks?

Item

2. The shape of your buttocks from the side (from the side view)?

Item

3. The shape of your buttocks?

Item

4. How smooth is your buttocks?

Item

5. The appearance of the buttocks skin?

CHEST MODULE
- SATISFACTION
WITH CHEST
Instruction
Response
option

The following questions ask about the appearance of your breast (breast area).
Note: If your chest (breast area) has a different shape on both sides, answer
questions about which side you are less satisfied with. Looking at your chest
(breast area) - over the last week - How satisfied or dissatisfied are you with the
following:
Completely dissatisfied
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Response
option
Response
option
Response
option

Fairly satisfied
Fully satisfied

Item

1. The shape of your chest (breast area) in a baggy T-shirt?

Item

2. The shape of your chest (breast area) when you lie on your back?

Item

3. How flat is your chest (breast area) when you stand upright?

Item
Item

4. How muscular is your chest (breast area)?
5. The shape of your chest (breast area) while you are in motion (for example:
running or jumping)?

Item

6. What does your chest (breast area) look like in soft T-shirts?

Item

7. The shape of your chest (breast area) without clothes?

Item

Item

8. What does your chest (breast area) look like when you are bent?
9. Is your chest (breast area) shaped from the side (from the side view) and you
are without clothes?
10. The shape of your chest (breast area) on the mirror while you are without
clothes?
If you had surgery in your chest (breast area), please answer the following
question:

Item

1- What are the scars resulting from surgery?

Item
Item

CHEST MODULE
- SATISFACTION
WITH NIPPLES

Somewhat dissatisfied

Instruction
Response
option
Response
option
Response
option
Response
option

The following questions ask about the shape of your nipples. Note: If your chest
(breast area) has a different shape on both sides, answer questions about which
side you are less satisfied with. Looking at how your nipples looked over the last
week, How satisfied or dissatisfied are you with the following:
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. The shape of your nipples?

Item

2. The size of your nipples?

Item

3. How flat are your nipples?
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Item

4. How soft do your nipples appear from your T-shirt?

Item

5. Your nipples shape without clothes?

Instruction
Response
option
Response
option
Response
option
Response
option
SATISFACTION
WITH UPPER
ARMS

Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. The size of your upper arms?

Item

2. How soft are your upper arms?

Item

3. The shape of your upper arms?

Item

4. The skin appearance on your upper arms?

Item

5. How aligned are your upper arms?

Item

6. What did your upper arms look like when you lifted them up?
7. What does your upper arms look like when they are not covered (for example:
wearing a sleeveless shirt)?

Item

SATISFACTION
WITH INNER
THIGHS

Circle only one answer for each question. Considering your upper arms - over
the last week - How satisfied or dissatisfied are you with the following::

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Considering your inner thighs - over
the last week - How satisfied or dissatisfied are you with the following::
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. How soft are your inner thighs?

Item

2. The appearance of your inner thighs skin?

Item

3. How aligned are your inner thighs?

Item

4. The appearance of your inner thighs when you are naked?
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SATISFACTION
WITH HIPS AND
OUTER THIGHS

Instruction
Response
option
Response
option
Response
option
Response
option

Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. The size of your outer hips and thighs?

Item

2. The shape of your outer hips and thighs?

Item

3. The appearance of your outer hips and thighs skin?

Item

4. How soft are your outer hips and thighs?

Item

5. The appearance of your outer hips and thighs on the back side?

Instruction
Response
option
Response
option
Response
option
Response
option
APPRAISAL OF
EXCESS SKIN

Circle only one answer for each question. Considering your outer hips and thighs
- over the last week - How satisfied or dissatisfied are you with the following:

Circle only one answer for each question. Considering excess sagging - over the
last week - how bothered you are:
Severe discomfort
Moderate discomfort
Slight discomfort

Item

I'm not upset at all
1. Increased sagging makes you look bigger than you are (meaning gaining
weight)?

Item

2. Do you need to wear clothes to hide excess sagging?

Item

3. Your inability to wear certain clothes due to excess sagging?

Item

4. The extent of excess sagging hanging from you?

Item

5. How much sag you have?

Item

6. Seeing people lose your excess sagging?

Item

7. What does your excess sagging look like when you are naked?
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Instruction
Response
option
Response
option
Response
option
Response
option

APPRAISAL OF
STRETCH
MARKS

APPRAISAL OF
BODY
CONTOURING
SCARS

Circle only one answer for each question. Consider your wrinkles - over the last
week - how bothered you are:
Severe discomfort
Moderate discomfort
little discomfort
I’m not bothered at all

Item

1. Are you unable to wear certain clothes due to wrinkles?

Item

2. How wide are your wrinkles?

Item

3. Do you need to wear clothes to hide wrinkles?

Item

4. The length of your wrinkles?

Item

5. Where are your wrinkles (places on your body)?

Item

6. How old are you looking like due to your wrinkles?

Item

7. How can you observe your wrinkles?

Item

8. How many wrinkles do you have?

Item

9. People can see your wrinkles?

Item

10. How is the look of your wrinkles up close?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. Consider your scars - over the last
week - how bothered are you:
Severe discomfort
Moderate discomfort
Slight discomfort
I'm not bothered at all

Item

1. Do you need to wear clothes to hide your scars?

Item

2. How wide are your scars?

Item

3. Where are your scars located?

Item

4. The length of your scars?
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Item

5. How noticeable are your scars?

Item

6. The color of your scars?

Item

7. How thick are your scars (i.e. bumpy or streaked)?

Item

8. The shape of your scars curled (not straight in shape)?

Item

9. People can see your scars?

Item

10. What do your scars look like when they're not covered by clothing?

Instruction
Response
option
Response
option
Response
option
Response
option

SATISFACTION
WITH
INFORMATION

Circle only one answer to each question. These questions inquire about
information you have received from your medical team (for example: your
surgeon, nursing, and staff) regarding your last surgery. How satisfied or
dissatisfied are you with the information you have received regarding the
following:
Completely dissatisfied
Somewhat dissatisfied
Fairly satisfied
Fully satisfied

Item

1. Quality of answers to your questions?

Item

2. How much information have you received written so that you can read it?

Item

3. Activities that you should avoid during the recovery period?

Item

4. How to perform the surgery?

Item

5. The length of time required for convalescence and recovery?

Item

6. Options for how to perform the surgery?

Item

7. The nature of the complications that may occur?

Item

8. The experience of other patients after having the same operation?

Item

9. How long will it take to fully recover?

Item

10. How much pain will you feel while recovering?

Instruction

Circle only one answer for each question. These questions ask about the surgeon
who performed your last operation. Did you feel that he / she:
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Response
option
Response
option
Response
option
Response
option

SATISFACTION
WITH DOCTOR/
SURGEON

SATISFACTION
WITH MEDICAL
TEAM

Never agree
Somewhat disagree
I somewhat agree
I definitely agree

Item

1. Behave in a professional manner?

Item

2. Speak to you in an easy-to-understand way?

Item

3. All your inquiries answered?

Item

4. Treat you with respect?

Item

5. Made you feel comfortable?

Item

6. Involve you in making decisions about your treatment?

Item

7. Listen to you and understand your concerns?

Item

8. Help you determine what works best for you?

Item

9. Was there to reassure your concerns?

Item

10. Spend enough time with you?

Instruction
Response
option
Response
option
Response
option
Response
option

Circle only one answer for each question. These questions ask about members of
the medical team other than your surgeon (for example: nurses and other
physicians) who participated in your last surgery. Did you feel that they:
Never agree
Somewhat disagree
I somewhat agree
I definitely agree

Item

1. Take care to protect your privacy?

Item

2. They treated with kindness and affection?

Item

3. Treat you with respect?

Item

4. They answered all your inquiries?

Item

5. Was it easy to talk to them?
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Item

6. Have they met your needs?

Item

7. You were distinguished by accuracy?

Item

8. Work together as a team?

Item

9. Have the required experience?

Item

10. Were there to reassure your concerns?

Instruction
Response
option
Response
option
Response
option
Response
option

SATISFACTION
WITH OFFICE
STAFF

COPYRIGHT

Circle only one answer for each question. These questions inquire about
members of the administration staff (for example: secretaries, receptionists)
who helped you during your last surgery. Did you feel that they:
Never agree
Somewhat disagree
I somewhat agree
I definitely agree

Item

1. Treat you with respect?

Item

2. They made you feel comfortable?

Item

3. Were they aware?

Item

4. Did they fulfill your desires?

Item

5. You were distinguished by accuracy?

Item

6. Work together as a team?

Item

7. They welcomed you at the front desk?

Item

8. Were they interested?

Item

9. They answered all your inquiries?

Item

10. Were there to reassure your concerns?

Copyright © 2013 Memorial Sloan Kettering Cancer Center - New York - USA. All
rights are reserved.

145

146

Curriculum Vitae
Name:

Khalifa Al-Ghanim

Post-secondary
Education and
Degrees:

The Royal College of Surgeons in Ireland (RCSI)
Dublin, Ireland
2012-2018 - MB, BCh, BAO, LRCP&SI
The University of Western Ontario
London, Ontario, Canada
2020- Present - MSc of Surgery

Honors and
Awards:

Western Graduate research Scholarship (WGRS)
2020-2021
LRCP Catalyst Grant for translational cancer research
(25,000 CAD) – 2020
National Surgical Skills competition - RCSI winner & National
Finalist – 2015 and 2016

Related Work
Experience

Resident Physician – Plastic and Reconstructive surgery
The University of Western Ontario
2021 – Present
Assistant Registrar – Plastic Surgery/ General Surgery
Department of Surgery, Jaber Al-Ahmed Hospital, Kuwait
2019- 2020
Intern Physician (Surgical)
Kuwait Institute of Medical Specializations
2018 - 2019

Publications:
1. AlGhanim, K., Al-Youha, S., AlWazzan, A. et al. Tranexamic acid in plastic
surgery: routes of administration and dosage considerations. Eur J Plast
Surg 44, 295–305 (2021). https://doi.org/10.1007/s00238-021-01794-5
2. ElAbd R, Samargandi OA, AlGhanim K, Alhamad S, Almazeedi S, Williams J,
AlSabah S, AlYouha S. Body Contouring Surgery Improves Weight Loss after
146

147

Bariatric Surgery: A Systematic Review and Meta-Analysis. Aesthetic Plast Surg.
2021 Jun;45(3):1064-1075. doi: 10.1007/s00266-020-02016-2. Epub 2020 Oct 23.
PMID: 33095301.
3. Al Sabah S, AlWazzan A, AlGhanim K, AlAbdulrazzaq HA, Al Haddad E. Does
Laparoscopic Sleeve Gastrectomy lead to Barrett's esophagus, 5-year
esophagogastroduodenoscopy findings: A retrospective cohort study. Ann Med
Surg (Lond). 2021 Jan 31;62:446-449. doi: 10.1016/j.amsu.2021.01.096. PMID:
33643643; PMCID: PMC7889435.

147

